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Abstract 
Based on vitamin B12 demand for proliferation, several prodrugs were built on B12 
scaffold. These include the rising metallodrugs (mainly Pt and Ru-based) and the 
more traditional organic chemotherapeutic drugs. Coordination chemistry is the focus 
of the project. Drugs or fluorophores were conjugated to the B12 scaffold either 
directly via CN--bridge or indirectly via a [trans-Pt(NH3)2-CN]+ bridge.1 This strategy 
allowed B12 to carry reasonably-sized molecules. The stability, reductive release and 
activity of these complexes were demonstrated. They remained high affinities with all 
cobalamin transport proteins. Their cellular accumulation was measured by attaching 
radioactive centers to their structures. Alternatively, the correlation of existing 
transition metals also reflected the cellular distribution of these complexes. It was 
found that charged complexes were preferably internalized into cells in a 
transcobalamin-independent pathway, which should be considered in future design of 
B12-prodrugs.
  
 
Zusammenfassung 
Vitamin B12 ist essentiel für den Vorgang der Zellteilung. Das Ziel dieser Arbeit ist 
die Synthese von B12 Derivativen, die die Zellteilung stark proliferierender Zellen, 
wie zum Beispiel Krebszellen, unterbinden oder verlangsamen. Diese Derivative 
beinhalten metallhaltige Pharmaka (hauptsächlich Pt- und Ru- basiert) sowie 
klassische organische Chemotherapeutika. Ein Schwerpunkt dieser Arbeit lag dabei 
auf der Entwicklung und Untersuchung der Koordinationschemie dieser B12 
Derivative. Pharmaka oder Fluorophore wurden direkt (CN--Brücke) oder indirekt 
[trans-Pt(NH3)2-CN]+ an das B12 Gerüst koordiniert. Diese Strategie erlaubte es dem 
B12 Derivativ das entsprechende Molekül zu transportieren. Des Weiteren konnte 
gezeigt werden, dass die Koordinierten Pharmaka oder Fluorophore reduktiv 
freigesetzt werde können und dabei ihre biologische Aktivität nicht verlieren. Trotz 
der strukturellen Modifikationen behalten die synthetisierten B12 Derivative ihre 
starken Affinitäten zu den Cobalamin-Transportproteinen. Das biologische Verhalten 
wurde durch eingefügte radioaktive Marker verfolgt, dabei wurde nachgewiesen, dass 
geladene Konjugate über einen Transcobalamin-unabhängigen Weg in die Zellen 
eingeschleust werden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abbreviation list 
ACN acetonitrile 
apo (apo-protein) a protein whose cofactor is absent 
Asp aspartic acid  
ATP adenosyltriphosphate 
bipy 2,2’-bipyridine 
Boc tert-butyloxycarbonyl  
oC degree Celsius  
C18 an octadecyl type of hydrocarbon 
ca. circa (approximately)  
CDI 1,1’-carbonyldiimidazole 
cDNA complementary DNA 
CDT 1,1’-carbonyldi(1,2,4-triazole) 
Ci curie 
COD cyclooctadiene 
Cp cyclopentadiene 
Cy cyanide dye 
CYP450 cytochrome P450 
d doublet 
Da Dalton 
DEE diethyl ether  
DMF N,N’-dimethyl formamide 
DMSO dimethyl sulfoxide  
DNA deoxyribonucleotide acid 
D2O deuterated water 
DSF Differential Scanning Fluorimetry 
DTPA diethylene triamine pentaacetic acid 
EDTA ethylenediaminetetraacetic acid 
en ethylenediamine 
ESI electron spray ionization 
et al. et alii (and others) 
EtOAc ethyl acetate 
  
EtOH ethanol 
FCS fetal calf serum 
g gravitational force unit 
h hour 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His histidine 
holo conjugate of apo-protein and its cofactor 
HPLC high performance liquid chromatography 
HSA human serum albumin 
Hz hertz 
IC50 half maximal inhibitory concentration 
ICP inductively coupled plasma 
IR infrared (spectroscopy) 
J coupling constant (Hz) 
LC50 lethal concentration, 50% 
K degree Kelvin 
Lys lysine 
m multiplet 
MeOD deuterated methanol 
MeOH methanol 
MS mass spectroscopy 
m/z mass to charge ratio 
NBD-CO-Hz 4-(N-Hydrazinocarbonylmethyl-N-methylamino)-7-nitro-2,1,3-
benzoxadiazole 
NCBI national center for biotechnology information 
NMR nuclear magnetic resonance (spectroscopy) 
PAMA picolylamine monoacetic acid 
PBS phosphate buffered saline  
PCR polymerase chain reaction 
phen phenanthroline 
ppm parts per million 
Rf retardation factor 
  
ROS reactive oxygen species 
RP reverse phase 
RPMI Roswell Park Memorial Institute medium 
r.t. room temperature 
s singlet 
SEC size-exclusion chromatography 
Ser Serine 
SN2 bimolecular nucleophilic substitution 
T Temperature 
TBTU o-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
tetrafluoroborate TEA riethylamine 
TEAP Triethyammonium phosphate 
terpy terpyridine 
TFA trifluoroacetic acid 
THA tetrahydroanthracene 
TrxR thioredoxin reductase 
U/ml units/milliliter 
vs. versus 
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I Introduction 
I.1 A “Noble” history 
The 19th and 20th century witnessed remarkable achievements in vitamin-related 
research. More than 10 Nobel prizes were conferred to the discoveries, isolation, 
synthesis and structural elucidation of vitamins A, B1, B2, B6, B12, C, D, E, and K. 
The concept of “vitamins”, which means “vital amines”, was established only in 
1911.2 It turned out that not all vitamins contain “amines”. In fact, different from 
other organic nutrients (proteins, fats, starch, and sugar), all vitamins share no 
common structural unit. The most complex structure of all vitamins belongs to 
vitamin B12. “The renaissance in the field of B12 research”, as described by Banerjee,3 
was highlighted with 3 Nobel prizes in a 30-year period (1934-1965). The discovery 
of B12 (Scheme 1) was acknowledged with a shared Nobel Prize for Whipple, Minot, 
and Murphy in 1934. The studies with anaemic dog led Whipple to propose liver as a 
rich source of a haematopoietic material, which can cure pernicious anaemia. Minot 
and Murphy subsequently translated the success to human anaemia.4 Concurrently, 
the isolation of pure “anti-pernicious anaemia factor” from liver was reported in 
1948.5, 6 Its structure was resolved by Dorothy Hodgkin.7, 8 This success brought her a 
Nobel Prize in 1964. In 1965, a Nobel Prize was awarded to Woodward, who 
subsequently achieved the chemical synthesis of B12 together with Eschenmoser in an 
effort involving more than a hundred scientists throughout 11 years.9 Scientists desire 
hitherto to understand every chemical property and biochemical process of B12.3, 10, 11 
Remarkable efforts were made to discover and elucidate structures of every B12-
related biomolecule. The gastric juice experiment allowed Castle to conclude that 
interaction between B12 (extrinsic factor) and a gastric juice factor (intrinsic factor) 
was required to reverse haematopoiesis.12 Following this discovery of intrinsic factor 
(IF), B12 complex transport pathway was gradually revealed.11, 13 The B12 “Noble” 
history is advancing to “a new medicinal era of vitamin B12”, as Randaccio 
proposed.14 
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Scheme 1: Structure of B12. 
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I.2 B12 coenzymes 
The coenzyme forms of B12 are methylcobalamin (Me-Cbl) and adenosylcobalamin 
(Ado-Cbl) (Scheme 2). A list of enzymes requiring the assistance of these two 
coenzymes can be found in (Table 1). There are actually only two B12-dependent 
enzymes in mammals, methionine synthase (MetH) and methylmalonyl Co-A mutase 
(MMCM).  
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Scheme 2: Structure of coenzyme B12: Me-Cbl (left) and Ado-Cbl (right). 
 
MetH is a modular protein with separate binding domains for homocysteine (Hcy), 
methyl tetrahydrofolate (Me-THF) (substrate regions), Me-Cbl (B12 binding region), 
and AdoMet (activation region). It catalyzes the conversion of Hcy to methionine 
using Me-THF as the methyl-source (Scheme 3).15 This process releases THF, which 
is required in DNA synthesis. Methionine is an essential amino acid. It can be 
converted to the methyl donor adenosyl methionine (AdoMet). The catalytic cycle of 
MetH involves two SN2 reactions. MetH accelerates the heterolytic cleavage of Co-C 
bond by a factor of 105-fold.16 Deprotonated Hcy acts as a nucleophile attacking on 
Me-Cbl to form methionine and Co(I)balamin. Me-THF is activated by protonation. 
The nucleophilic Co(I)balamin could, in theory, attack either proton or methyl group. 
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As Co(I)balamin is weakly basic (pKa~1),17 the latter is opted to regenerate Me-Cbl.18 
Oxidative inactivation occurs once per 2000 turnovers resulting in Co(II)balamin, 
which interacts with AdoMet and MetH-reductase to regenerate Me-Cbl.19  
MMCM catalyzes the interchange between the carbonyl-CoA group and a hydrogen 
from the vicinal carbon (Scheme 3). MMCM requires homolysis of Co-C bond in 
Ado-Cbl. Though this bond is inherently weak with a bond dissociation energy of 
approximately 30 kCal/mol,20 the enzyme even accelerates homolysis by a factor of 
ca. 1012. The enzyme binding probably creates strain in the structure of Ado-Cbl. 
Homolysis results in two radicals, deoxyadenosyl and Co(II)balamin.21 The former 
abstracts hydrogen from the methyl group of methylmalonyl-CoA. The yielded 
radical undergoes 1,2-rearrangement with the neighbouring carbon, which 
subsequently reabstracts a hydrogen from 5’-deoxyadenosine. Ado-Cbl is reproduced 
by the combination of 5’-deoxyadenosyl and Co(II)balamin radicals.20  
In the holo- forms of both enzymes, the lower α-dimethylbenzimidazole (α-DMB) 
was replaced by His, which forms ligand triad with another two amino acids via 
hydrogen bonds. In MetH, the ligand triad includes His759, Asp757, and Ser81022 
whereas His610, Asp608, and Lys604 form the ligand triad of MMCM.23 
Coordination of His to the cobalt center does not result in a stronger trans-effect on 
the β-ligand. The role played by the ligand triad indeed remains unclear and so is the 
mechanism, under which the enzymes determines the fate of Co-C bond.24  
 
 
 
 
Introduction 
  
5 
CH3
CoIII
N
N
CoI
HN
N N
H
N
O
H2N
H NHAr
HN
N N
H
N
O
H2N
CH3 NHAr
S CO2-
+H3N
H
S CO2-
+H3N
H3C
N N
N
N
NH2
O
OH
HO
H2C
S+
H
NH3+
CO2-
N N
N
N
NH2
O
OH
HO
H2C
S+
H3C
NH3+
CO2-
CoII
N
N CoI
O2
O2- Flavodoxin oxidizedFlavodoxin reduced
tetrahydrofolate
N-methyltetrahydrofolate
homocysteine
methionine
Adohomocysteine
Adomethionine
REACTION 1 REACTION 2
REACTION 3
 
 
CoII X X C CH2
COSCoAHH
HOOC
XH C CH2
COSCoAH
HOOC
C CH2
H
HOOC
COSCoA
XHC CH2
H
HOOC
COSCoA
H
X
CoIII
X
X   =
N N
N
N
NH2
O
OH
HO
H2C
 
 
Scheme 3: Coenzymatic mechanism of Me-Cbl (above) and Ado-Cbl (below). 
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Table 1: List of B12-dependent enzymes. 
 
Coenzyme
  
Enzyme class Enzyme Required 
additional 
coenzyme 
Coenzyme-
enzyme 
binding mode 
MetH 
 
Zn2+ Me-Cbl Methyl-
transferases 
Enzymes involving in 
CO2 fixing pathway 
[Fe4S4] 
cluster 
Base-off/ His-
on 
Eliminases  K+ Base-on 
Ribonucleotide reductase 
(RNR) 
K+ Base-on Mutases/ 
Isomerases 
MMCM,  
isobutyril-CoA mutase, 
glutamate mutase, 
methylene glutarate 
mutase, 
ethanolamine ammonia 
lyase,  
D-ornithine aminomutase, 
ß-lysine mutase,  
diol dehydrase,  
glycerol dehydratase 
 Base-off/ His-
on 
Ado-Cbl 
Reductive 
dehalogenases 
 [Fe4S4], 
[Fe3S4] 
clusters 
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I.3 Transport and metabolism of cobalamin 
It is with great care that the body handles precious amounts of Cbl. Concerted 
involvement of many proteins in the extra- and intracellular journeys of Cbl was 
revealed. The former includes haptocorrin (HC), intrinsic factor (IF), and TC. The 
holo-proteins are recognized by corresponding receptors: asiaglycoprotein (ASGP-R) 
(41 or 46 kDa), cubilin (460 kDa), TC-receptor (TC-R) (58 kDa) and megalin (600 
kDa) (Table 2).13 Except for AGPR, other receptors recognize only holo-proteins. 
AGPR accepts both holo-and apo-HC and accounts for liver uptake of HC. Besides, it 
binds indeed to all glycoproteins with terminal galactose residues. Its absence does 
not result in B12 deficiency.  
 
Receptors
  
Expression sites  
AGPR Liver, intestine, colon carcinoma (HT-29, Caco-2)25, 26  
Cubilin Intestine mucosa, kidney proximal tubule, yolk sac, etc27, 28  
TC-R All tissues,29-31 Overexpression: kidney, liver, placenta, intestine and 
fast-growing cells.31-34 
Megalin Renal proximal tubule epithelium, other absorptive epithelia (brain 
ependyma, yolk sac epithelium, placenta, lung).35  
 
Table 2: Expression sites of receptors. 
 
Following its oral intake, Cbl is associated with HC.36, 37 Pancreatic enzyme degrades 
HC and Cbl is transferred to IF.38 As Cbl-IF interaction is highly specific, 39-42 IF 
excludes unusual Cbl analogues from plasma entrance. Holo-IF crosses enterocytes, 
where IF is degraded and free Cbl is released to plasma (Scheme 4). In plasma, ca. 
20% of Cbl is captured by TC.43, 44 Holo-TC is then distributed to most of the tissues 
via TC-R. In addition, it is recycled from primary urine by megalin receptor. The 
major amount (80%) of plasma Cbl is, however, in complex with HC. HC possibly 
serves as a second filter to exclude analogous Cbls from tissue distribution. Also, it 
can mediate the storage of Cbl in liver. The exact role of HC remains to be 
elucidated.25, 45 
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Scheme 4: Uptake and transport of B12.11  
 
Scheme 5 shows cellular import and export of Cbl in polarized vs. non-polarized 
cells. The two cell types share the same Cbl export mechanism (via MRP1). The 
cellular entrance of Cbl, however, is different. In both cases, the receptors (cubilin 
and TC-R) are recycled whilst the transport proteins (IF and TC) are degraded in 
lysosome. Free Cbl exits lysosome via LMBD1. Decyanation of B12 and dealkylation 
of alkyl-Cbl occur through binding to MMACHC in cytosol. MMADHC subsequently 
drives Cbl to its mitochondrion and cytosol pathway. In cytosol, cob(II)alamin binds 
to MetH and MetH-reductase subsequently catalyzes the formation of Me-Cbl. In the 
mitochondrion, MMAB catalyzes the formation of Ado-Cbl, which is then transferred 
to MMCM.46 
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Scheme 5: Uptake and exit of B12 in polarized (above) and non-polarized cells.11 
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I.4 Structure of cobalamin 
“B12 turned out to be a substance of frightening complexity” (Lord Todd) 
Cbl is an octahedral complex of CoIII with a tetradentate corrin ring, an α-nucleotide 
loop, and an exchangeable ß-ligand.47 The corrin consists of 4 reduced pyrrole rings 
with a direct connection between A and D rings (Scheme 6). It folds upward around 
the Co-C10 axis. The folding angle ranges from 1.9-23.9o (17.9o, 14.8o, and 10o in 
case of B12, Me-Cbl, and Ado-Cbl, accordingly). The bulk of α-ligand and the Co-
N(α) bond length (2.19 and 2.21Å in Me-Cbl and Ado-Cbl) regulate the corrin 
folding. The corrin, on the other hand, exerts a labilizing cis-effect on axial ligands. 
The trans-effect of the ß-ligand indirectly influences the α-ligand via Co-N(α) bond 
length. 
The semicovalent Co-C bond in B12 conezymes is unusually stable, which is 
attributed to the dominance of Co 4s (instead of 3d) orbital in ligand bonding.48 Its 
coenzymatic function was triggered when the CoIII center is reduced stepwise to form 
square pyramid cob(II)alamin and square planar cob(I)alamin.49, 50 The latter is a 
supernucleophile. It involves in several SN2 reaction including attacking ATP to form 
Ado-Cbl or attacking Me-THF to form Me-Cbl. 
The decrease in cobalt oxidation state is accompanied by the decrease in coordination 
number. The ß-ligand is more susceptible to reductive cleavage than the α-loop. 
Reoxidization recovers the octahedral geometry.17 Coenzymes B12 are formed by 
displacement of the ß-ligand with either a methyl or an adenosyl group.51, 52 
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Scheme 6: B12 numbering scheme. 
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I.5 Cobalamin conjugates 
The demand of Cbl in proliferation process was applied to cancer treatment in various 
strategies. Among those was the inactivation of B12-dependent MetH by N2O,53-56 the 
inhibition of B12 by its antagonists including B12-[c-lactam]57 and B12 with peptide 
backbone.58, 59 The most common strategy is, however, to attach cytotoxic molecules 
to B12 structure. Drugs and analytical probes were readily introduced to the B12 
structure through numerous functional groups on the corrin side chains.60. Radioactive 
111In-DTPA and 99mTc-DTPA were coupled to B12 via the b-side chain.61, 62 
[99mTc(CO)3]+ moiety was coupled to B12 at b and d-positions.63 Biotin was 
conjugated to B12 at b, c, d, and e positions (Scheme 6).60 In addition, the ß-position is 
especially common owing to its ease-of-release in cellular reducing environment and 
its little involvement in protein binding (1 and Scheme 7). The ribose-OH group is 
another convenient derivatization site (Scheme 6) as its role in protein interaction is 
also not critical.64 Indeed, fluorophores65, 66(Scheme 8), cytotoxic agents,67insulin,68 
and appetite suppressing peptide hPYY,69 were coupled to B12 via the ribose-
hydroxyl.  The increasing structural knowledge of Cbl and related proteins laid the 
background to fine-tune designs of B12 derivatives. Tissue distribution was interfered 
by modifying B12 structure at critical sites of protein interaction such as b- or d-side 
chain of the corrin.70  
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Scheme 7: Drugs conjugated to Cbl: (a) nitrogen mustard chlorambucil,71 (b) 
colchicine,72 (c) insulinomimetic vanadate (V) compound,73 (d) nitric oxide.74 
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Scheme 8:  Some fluorescent B12 with: fluorescent nucleoside(a),75 dansyl derivative 
(b),75 fluorescein (c, d),76 Rhodamin 6G (e),65 Cy5 (f),77 Re(I)-based-fluorophore(g).78 
 
A great deal of researches was dedicated to discover and explore the correlation of 
B12 demand and DNA synthesis. It should, however, be noted that B12 can also lend 
other interesting properties to its conjugated molecules. Its excellent water solubility 
allowed convenient administration of the attached insoluble drugs.79 B12 protected 
protein-peptide drugs68, 69, 80 from hydrolysis in the acidic condition of the 
gastrointestinal track.81 The utilization of Cbl in transporting drugs appeared to be 
restrained by its cellular loading capacity.82 Different strategies were applied to 
overcome this limitation. Minimization of competitive background B12 was achieved 
in-vitro by depriving B12 and folic acid from culture medium.83 This corresponded to 
a B12-free diet in in-vivo experiments.70 Besides, increase in TC-R expression was 
induced by interferon ß (IFN-ß).74 A greater number of TC-R would endocytose a 
higher amount of Cbl. The addition of IFN-ß had a synergistic effect on both in-vitro 
and in-vivo cytotoxicity of nitrosyl-Cbl. B12 overdosing was another treatment regime. 
A recent study showed that tissue accumulation of B12 increased significantly (up to  
350%) upon overdosing of the vitamin.84  
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I.6 Metal anticancer drugs 
I.6.1 Gold anticancer drugs 
Gold found application in ancient medicine in China, India, and Egypt before any 
scientific rationalization was established in the 20th century. Both Au(I)- and Au(III)-
complexes were widely studied for anticancer activity (Scheme 9).85 ”Soft” ligands 
with S and P as donor atoms are popular for Au(I)-complexes. ”Hard” ligands with O, 
N, or C as donor atoms were more compatible to the highly oxidizing Au(III) as ”soft 
ligands” are generally reducing. Failure in translation from in-vitro cytotoxicity to in-
vivo antitumor profile hampered the development of Au(I)-complexes in cancer 
research as they were bound to serum proteins. Au(III)-complexes were expected to 
have interesting properties owing to the isoelectronic (d8) and isostructural (square 
planar) relation to Pt(II). Though interesting cytotoxic profiles were reported, Au(III)-
complexes were found to act differently from cisplatin as DNA is not their primary 
target.86, 87  
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Scheme 9: Structures of some Au(III) and Au(I) complexes: (a) [Au(phen)Cl2]Cl, 
[Au(terpy)Cl2]Cl,88 and Auranofin.89 
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I.6.2 Ruthenium anticancer drugs 
The most prominent non-Pt metal-based cancer drugs are probably Ru-complexes 
with novel properties: i) Ru various oxidation states (II, III, and IV), ii) tumor 
accumulation, iii) antimestatic effects, iv) slow ligand exchange kinetics, and v) good 
biocompatibility (owing to iron micmicking). The most interesting Ru(III)-complexes 
were the anti-metastatic NAMI-A and the cytotoxic KP1019 (Scheme 10) with 
established data from clinical phase-I study.90-92 Even though Ru(II)-complexes were 
considered to be more active than Ru(III)-complexes, suitable ligand selection proved 
to enhance the stability. Most noticeable among Ru(II)-complexes were Ru(II)-arene 
compounds from Sadler’s and Dyson’s groups (Scheme 10), Ru(II)-half-sandwich 
and antimestatic Ru(II)-RAPTA-complexes, correspondingly.93, 94 Despite similar 
structural aspects, they exert different effects on tumour via distinct modes of action. 
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Scheme 10: Structures of some Ru-drugs: (a) [Ru(phen)(en)Cl][PF6], (b) [Ru(bipy) 
(en)Cl][PF6], (c) [Ru(THA)(en)Cl][PF6],95 (d) RuRAPTA,96 (e) NAMI-A, and (f) 
KP1019.97 
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I.7 Organic anticancer drugs 
Cytarabine (Cyt), an analogue of the nucleoside deoxycytidine (Scheme 11), was 
approved for the treatment of myeloid leukemia and non-Hodgkin’s lymphoma.98, 99 It 
is metabolized to its triphosphate form at 5’-OH position and respectively competes 
with deoxycytidine triphosphate in DNA synthesis. Cyt, however, represents a 
challenge for tumor targeting due to its short plasma half-life, low stability and 
limited bioavailability. Low membrane permeability and the ease to be inactivated by 
cytidine deaminase at the 4-N position limit its therapeutic efficiency.100  
O
OH
OH
HO
N
N
NH2
O
O
OH
HO
N
N
NH2
O
4-N
5'-OH
 
 
Scheme 11: Structure of Cyt (left) and deoxycytidine (right) 
 
Extensive research on targeted delivery of Cyt includes conjugation with amino acids, 
fatty acids, and phosphates at either 4-N or 5’-OH site to prevent drug degradation 
and enhance membrane permeability. Among these formulations are hydrogels, 
liposomes and niosomes. Encapsulation maintains chemical integrity of the drug and 
enhances membrane transport. Nevertheless, it is the ability to liberate drugs, which 
determines success of such delivery system. Strong interactions of Cyt with hydrogels 
and niosomes lead to poor drug release. Only liposome, with its enhanced 
permeability and retention (EPR) effect, was shown to be a relevant delivery system 
for Cyt.101 
Dacarbazine (Dac) is a melanoma and Hodgkin’s disease drug. Several mechanisms 
of actions were suggested for Dac including methylating DNA, interacting with SH 
groups, and inducing ROS formation.102, 103 Dac, however, is mostly referred as a 
DNA alkylation agent. It is activated to MTIC by the liver enzyme CYP450.104 The 
electrophilic methyl group is attacked by the nucleophlic N-7 and O-6 of guanine 
(Scheme 12).105, 106 
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Scheme 12: Methylating mechanism of Dac on N-7 of guanine.103  
 
Anastrazole (Ana) is prescribed for post-menopausal women with hormone receptor 
positive early breast cancer. Ana binds reversibly to the heme iron of aromatase 
(Scheme 13) and, thus, inhibits the aromatase-dependent synthesis of estradiol 
(E2).107 As hormone receptor positive breast tumors depend on E2 for their growth, 
the interference with E2 synthesis suppresses proliferation.108  
 
 
Scheme 13: Mechanism of action of Ana.108  
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I.8 Imaging angents 
Several fluorophores were conjugated to B12 via either Co-C bond or ribose 5’-OH 
(Scheme 8). B12 was known to exert a quenching effect, completely75 or partially.76, 78 
Most clearly is the fact that the fluorescence of α-ribazole (1-α-D-ribofuranosyl-5,6-
DMB) was not observed in Cbl structure. Also, B12 completely quenched several 
different fluorophores attached as ß-nucleosides or ß-alkyls.75 Interaction between 
fluorophores and the corrin macrocycle accounted for the loss of fluorescence. 
Orienting the fluorophores away from the corrin was reported to prevent the 
quenching effect of B12.65  
Several radionuclides were coupled to B12 structure for TC-R imaging and 
biodistribution study. These included both ß- and γ-emitters: [57Co], [125I], [131I], 
[111In], and [99mTc].  Conjugation sites varied from corrin side chains (b, d, e)61-63 to ß 
-axial position.109 Despite the commercial availability of [57Co]-B12, it is not suitable 
for clinical imaging. The long half-life (270.9 days) of 57Co results in low specific 
activity (1 µCi/µg). Radioisotopes with short half-life and high specific activity are 
prefered. γ-rays are less harmful to tissues than ß-particles. Therefore, [125I], [111In], 
and [99mTc] are favored over [131I]. [99mTc], with an optimal γ-energy (142 keV) and a 
short half-life (6 h), is the most important radioisotope in nuclear medicine. 
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II Objectives 
The aim of this thesis was to produce, in a coordination chemistry approach, 
therapeutic and diagnostic B12 derivatives for cancer research. Antitumor metal 
complexes such as cisplatin and ruthenium (II) arene compounds were directly 
conjugated to B12 via ß-CN-. Organic chemotherapeutic drugs or fluorophores were 
coordinated to B12 via ß-[trans-Pt(NH3)2-CN]+-bridge (Scheme 14). Radioimaging 
agents [99mTc] were introduced to the corrin side chain or the back loop (ribose). This 
allows the cellular behavior of these compounds to be studied. Besides, direct 
measurements of transition metals in these compounds also provided information of 
their cellular process. The release of native drugs was studied by reduction 
experiments, both electrochemically and chemically, in combination with HPLC and 
ESI-MS techniques. Cytotoxicity was compared among native drugs, prodrugs, and 
the released drugs. 
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Scheme 14: B12 conjugates to deliver active metal complexes (left and middle) or 
active organic compounds (Y) (right).
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III Results and discussion 
III.1 {Metallodrug}-{B12} conjugates 
The ß-side modification of Cbl was mainly at the photo-instable organometallic Co-
C(alkyl) bond. The handling of alkyl-Cbl is rather complicated.110 The stronger Co-
CN bond represents a better modification site.111 Indeed stable complexes were 
previously synthesized by coordinating ß-CN- to [M(OH2)(L2)(CO)3] (M = Re, 
99mTc)112 and [PtClx(NH3)4-x] (x=1-3).113 We therefore continue this strategy on 
recently rising anticancer metallodrugs. The presence of a labile ligand is required for 
substitution by the nucleophilic ß-CN-. This feature is common in many metallodrugs 
(Scheme 10 and Scheme 15) as they were designed to mimick the action mechanism 
of cisplatin.  
In this thesis, B12 was coordinated to the increasingly important Ru- and Au- 
anticancer compounds. The products, if stable, would inherit the novel physical, 
chemical and biological properties of B12 such as water solubility, steric feature, 
biocompatibility, and proliferation targeting. 
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Scheme 15: Structures of titanocene dichloride (left), cis- and trans-[RuCl2(DMSO)4] 
(middle and right, accordingly).
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III.1.1 {[Ru]-drug}-{B12} conjugate 
[(η6-arene)Ru(en)Cl][PF6] (Scheme 10) was selected as a candidate of Ru-arene-
drugs for coordination of B12. Similar to cisplatin, it was activated by the intracellular 
hydrolysis of Ru-Cl bond, which allowed coordination of N7-guanine nucleophile to 
Ru. In addition, the en-NH2 formed hydrogen bond to O6-guanine and the arene 
intercalates with DNA (Scheme 16).114, 115 It could obviously be predicted that the 
substitution of Cl- by ß-CN- might influence the N7-guanine binding. However, this 
does not necessarily mean deterioration of DNA interaction, as en and the 
hydrophobic arene are still available. The rich collection of Ru-arene drugs from 
literature promises a wide range of {[Ru]-drugs}-{B12} compounds.  
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Scheme 16: Interaction of [Ru(arene)(en)]2+ with nucleobases.115 
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Formation of the sandwich coordinative compound [{(η6-C6H6)Ru(en)}-{B12}][PF6]2 
3 was, on the structural perspective, interesting. A shift of νCN to higher energy in IR 
spectroscopy indicated the coordination of {Ru} to CN-. Whereas the correct mass on 
ESI-MS showed the formation of 3, the additional strong signal in 1H-NMR’s 
aromatic region besides the 5 signals of B12 (C10, R1, B7, B2, and B4) was a definite 
characteristic proof  of  3 (Figure 1). 
 
 
Figure 1: 1H-NMR spectrum of [{(η6-C6H6)Ru(en)}-{B12}]2+. 
 
The most traditional technique for B12 separation and purification, chromatography, 
was not reliable as 3 decomposed through C18-columns. Despite its distinguishable 
earlier retention time with respect to that of B12, the collected HPLC fraction turned 
out to be B12 on ESI-MS and IR, indicating that the Ru-fragment was cleaved from 
B12 during the elution. It was likely bound to the silanol residues of the column. The 
decomposition of organometallic compounds during chromatographic separation has 
previously been described.116 The reaction was monitored by HPLC but purification 
must be done by another method. Therefore 3 was precipitated from water solution 
with the counter ion [PF6]-. The product did not completely precipitate in water. It 
dissolved partially and appeared to be less stable than {cis/transplatin}-{B12} 
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conjugates, 1 and 2. In details, 30%, 48%, and 63% of 3 (0.16µM) were decomposed 
to B12. Indeed [(η6-C6H6)Ru(en)]2+ is more sterically demanding than [Pt(NH3)2Cl]+, 
which may account for its lower stability. Coordination of B12 to the even more bulky 
[(η6-p-cymene)Ru(en)]2+  or [(η6-THA)Ru(en)]2+ (Scheme 10) was attempted but 
unsuccessful. As the cytotoxicity of Ru-arene drugs correlates to the arene 
lipophilicity/ bulkiness,117 sufficiently stable {Ru-arene}-{B12} compounds are 
therefore unlikely.  
B12 was also coordinated to Ru-RAPTA-C (Scheme 10). The product formation was 
evident from IR and ESI-MS measurements. However, it could not be isolated. The 
increasing water solubility of Ru-RAPTA-C made it impossible to precipitate {Ru-
RAPTA-C}-{B12} (Scheme 17). It was similar to {(Cp*)Rh(Cl2)}-{B12}, the 
formation of which was observed (IR, ESI-MS) after mixing [RhCl2Cp*]2 with B12 in 
MeOH. Purification was not possible due to decomposition on HPLC column. 
Purification by precipitation with a counter-ion did not apply as {(Cp*)Rh(Cl2)}-
{B12} is a neutral compound (Scheme 17).  
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Scheme 17: Unpurified [B12]-[(Cp*)Rh(Cl2)] (left) and [B12]-[Ru-RAPTA-C] (right).
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III.1.2 {[Au]-drug}-{B12} conjugate 
The [Au(phen)Cl2]Cl complex118 (Scheme 9) represents a physiologically stable class 
of Au(III) complexes owing to the presence of the multidentate ligand phen. It was 
reported active against cisplatin-resistant cancer cell line88 owing to its different 
cytotoxic mode, which was ascribed to the released phen under reducing condition in 
mammals.88 However, it was ca. 3 times less cytotoxic than cisplatin in cisplatin-
sensitive cell line. 
ß-CN- did not substitute the Cl- ligand in [Au(phen)Cl2]+. Efforts included performing 
reactions directly between B12 and [Au(phen)Cl2]Cl in MeOH, H2O, DMF: H2O (1:1), 
or H2O at physiological pH (phosphate buffer), prolonged reaction time, and vigorous 
heating (up to 75oC). Alternatively, Cl- was removed by AgNO3 before B12 was 
added. However, no coordination was observed. [Au(phen)Cl2]Cl was poorly soluble. 
Longer reaction time and higher temperature resulted in decomposition of B12 to Cbl-
OH2. It was shown previously that the Cl- ligand is rather easily released.88 Therefore, 
the sterically demanding ligand B12 was likely to be the obstacle. As [Au]-drugs are 
generally bulky, the formation of stable {[Au]-drugs}-{B12} complexes is thus 
unlikely.85  
In summary, B12 is a bulky ligand. The corrin upward folding and its sentinel groups 
place certain dimensional confinement on the ß-axial ligands.47 Commonly-found 
spacious structures of metallodrugs fit hardly in the allowed pocket of the ß-face.113 
Bulky complexes were not able to accommodate the sterically demanding B12 ligand. 
Pt(COD)Cl2, [Au(phen)Cl2]Cl, [(η6-p-cymene)Ru(en)Cl][PF6], and [(η6-
THA)Ru(en)Cl][PF6] were such examples. Stable {Metallodrug}-{B12} complexes 
can be achieved with reasonably-sized {Metallodrug}. Computer modeling can 
certainly support the screening of a suitable {Metallodrug}.
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III.2 {Organic-drug}-{B12} double prodrugs 
III.2.1 Synthesis of B12 double prodrugs 
Traditional drugs are mainly organic compounds. It is therefore interesting to 
conjugate these compounds to B12. A coordination chemistry approach to this goal 
was using transplatin as a mediator for conjugating of B12 and organic drugs.  
Transplatin was selected to reduce {drug}-{B12} steric interaction. The strong trans-
effect of CN- labilizes the trans-Cl-, which can then be substituted by a strong 
incoming ligand. On the other hand, CN- also labilizes the new group, which can be 
released under suitable conditions. However, substitution reactions with 2 are 
competed by decomposition of 2 at elevated temperature. At temperatures > 50oC or 
reaction times > 1 day, 2 decomposes. The ß-axial ligand was replaced by water 
yielding Cbl-OH2 as evident from HPLC detection. The syntheses of 4-6 were, 
therefore, performed at high concentration (10-30 mg/ml of 2) and at T< 40oC. In case 
of 5, HPLC and ESI-MS evidenced cleavage of methyl groups in Dac at T~ 50oC.  
The chemical shifts of the five aromatic protons in B12 were preserved whereas those 
of the additional aromatic protons from Cyt, Dac and Ana were detected in the correct 
respective ratios (Figure 2 and Appendices). Resulting from the shielding effect of the 
new ligands Cyt, Dac and Ana in 4-6, the platinum signal (195Pt-NMR) is shifted 
upfield.79, 113, 119, 120 Cyt, Dac, and Ana rendered 4-6 more lipophilic as compared to 2. 
This resulted in good HPLC separation from the starting material 2, B12, and Cbl-OH2 
(Figure 3).  
Whereas Dac and Ana dissolve slightly in water, 4-6 exhibit very good water 
solubility. Thus, water insoluble organic drugs can become water soluble when bound 
to B12 as carrier. These compounds are prodrugs since the platinum complex as well 
as the organic drugs can be released from B12 (vide infra). Newly-designed prodrugs 
must generally meet at least three requirements to be biologically applicable; i) 
sufficient plasma stability to ensure prodrug integrity until targeted organs are 
reached, ii) chemical modification must not influence the intended targeting 
properties, and iii) drugs must be released inside targeted organs to exhibit therapeutic 
activities. These criteria apply also for double prodrugs with two-step release 
mechanisms. Since targeted delivery of Cyt has attracted great attention, 4 was 
selected to further study the compliance with these three requirements.
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Figure 2: 1H-NMR spectrum of cytarabine conjugated to B12 via transplatin linker 4.  
 
 
Figure 3: HPLC separation of compounds 4-6 from the starting material 2, B12, and 
Cbl-OH2. 
 
N N
NN
Co
C
H2NOC
H3C
H3C
H
H2NOC
H3C
HN
O
O
H
H3C
P
OO
O O
OH
HO N
N CH3
CH3
CH3
CONH2
CH3
CH3
CH3
CONH2
CONH2
CH3
H2NOC
N
Pt NH3H3N
N
NO NH2
O
HO
OH
OH
2
(4)
Results and discussion 
  
27 
III.2.2 Stability of B12 double prodrugs 
Following previous B12-prodrugs,79, 113 the plasma stability of 4 was examined 
through binding to HSA in physiological conditions. The stability was monitored 
daily on HPLC columns 1 and 2 throughout a three-day period. Decomposition of 
compound 4 resulted in B12 and platinated cytarabine species, which were detectable 
on RP-HPLC. In parallel, SEC-HPLC monitored variation of the ratio between the 
high and low molecular weight signals. After 3 days, ca. 3% of 4 or its decomposition 
products were bound to HSA, ca. 2.7% was present as free B12. It is known that B12 
does not bind significantly to HSA.113 A blank experiment with B12 showed ca. 1-2% 
associated to HSA under the same experimental condition. The observed HSA affinity 
is therefore not related to B12. In fact, Cbl-OH2 as released after cleavage of [{trans-
CN-Pt(NH3)2}-{Cyt}]+ exposed an available coordination site which is prone to be 
substituted by S- and N-donor sites from HSA.121 Besides, the compound 4 can form 
lipophilic interaction with HSA similarly to B12.113 The 3% HSA binding capacity of 
4 underlines its higher stability with respect to 2, which holds 11% HSA binding 
capacity only after 1 day. The Cl- ligand in 2 is obviously faster replaced by HSA 
 than the aromatic amines in 4-6.79, 113  
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III.2.3 Affinity of B12 double prodrugs to B12 transport proteins 
To assess requirement ii) for prodrugs, the binding properties of 4 to B12 transport 
proteins were studied by DSF technique. TC binding is crucial for targeting tumors 
with over-expression of TC-Rs. The Cbl-affinities and specificities are high towards 
IF122 and TC45 whereas HC is known to tolerate even substantial variations of Cbl 
structures.41 For example, cobinamide (Cbi) still binds firmly to HC albeit the absence 
of the nucleotide loop (Scheme 18).42 In contrast, IF and TC do not binding to Cbi 
since the structure alterations are too substantial. 
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Scheme 18: Structure of Cbi. 
 
In DSF technique, a fluorescent dye interacts with the hydrophobic sites of proteins 
upon thermal unfolding. The melting temperature (Tm) of proteins can be inferred 
from the recorded fluorescence curves.123 Differences in Tm between the ligand-bound 
and free forms of proteins (ΔTm) indicate ligand-protein affinity. By comparing the 
measured ΔTm values for 4-6 to the obtained values with B12 and Cbi, the affinity 
could be concluded. Despite the presence of rather bulky ß-axial groups, 4-6 
maintained good affinity to the B12 transport proteins, indicated by similar ΔTm values 
as measured for B12 (Figure 4). The ΔTm values for HC binding were ~ 16°C for 4, ~ 
19°C for 5, ~ 15°C for 6, and ~ 22°C for B12. In case of TC, ΔTm for B12 is ~ 12°C, 
which compares well with ~ 10°C for 4-6. The same situation was also found with IF. 
B12 and 4-6 hold similar ΔTm ~ 7-8°C. None of the compounds 4-6 showed similar 
Results and discussion 
  
29 
ΔTm to those of Cbi in case of TC and IF (~ 1-2°C). These results strongly indicated 
potential binding of 4-6 to all B12 transport proteins. 
 
Figure 4: Thermal shift of 4-6, B12, and Cbi to Cbl transport proteins. 
 
All three transport proteins are known to have two-domain structures.124 The crystal 
structure of holo-TC revealed that Cbl is captured in a cleft between these two 
domains. The Cbl binding sites of the protein interact with all side chains of the corrin 
ring and two oxygen atoms of the phosphate group. The ß-axial group and the 5’-OH 
group on the nucleotide ribose are not involved in Cbl-TC interaction (Scheme 19). 
These positions are, as in this study, attractive for derivatizations without affecting 
affinities.64 The ΔTm values found with 4-6 confirm this concept and are coincident 
with a number of other B12 derivatives for diagnostic and therapeutic purposes.66, 67, 72, 
73, 76, 112, 122 
 
Scheme 19: Cbl bound to two domains of bovine TC: the corrin plane lied 
perpendicular to the domain interface. Histidine displaced water at ß-position.125 
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III.2.4 Reductive release of drugs from B12 double prodrugs 
In the cellular environment, CoIII in B12 is reduced to CoII, resulting in the cleavage of 
the β-axial ligand.126 As we have shown in different assays, pure [PtII]-complexes are 
cleanly freed through this process. The release of Cyt together with the PtII complex 
from 4 was achieved by electrochemical and chemical reduction. At -700 mV, 
UV/Vis spectroscopy revealed a gradual increase of the absorbance at 476 nm and a 
decrease at 361 nm, an indicative feature for reduction of CoIII → CoII (Figure 5).  
 
Figure 5: UV spectra changes in the reduction of 4 at -700mV  (left) and after 
reduction with Zn/NH4Cl (red, right) followed by reoxidization (black, right) 
 
Chemically, 4 was reduced with Zn° and subsequently reoxidized in air. The 
formation of Cbl-OH2 was confirmed by absorbance maximum at 356 nm (Figure 5) 
and the detection of a Cbl-OH2 peak in HPLC chromatogram. Besides the peak for 
Cbl-OH2, a species was eluted at a retention time similar to Cyt (Figure 6).  
 
Figure 6: HPLC chromatograms of the product mix from reduction of 4 with 
Zn/NH4Cl. 
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An ESI-MS spectrum of the complete raw reaction mixture after chemical reduction 
evidenced [M+1]+ of Cyt (244.7), [M-H2O+1]2+ of Cbl-OH2 (665.1), and [M]+ of 
[trans-Cyt-CN-Pt(NH3)2]+ (498.2) (Figure 7). Over extended time period, ESI-MS 
evidenced disappearance of the [trans-CN-Pt(NH3)2}-{Cyt}]+ signal whereas the 
signals of Cbl-OH2 and Cyt persisted. A signal of Cyt dimer (487.2) also appeared 
(Figure 7), which could either be an artifact obtained during ionization process in the 
MS or a by-product of prolonged stirring the reaction mixture. In summary, the 
reduction of CoIII→CoII leads to cleavage of the entire ß-axial ligand [trans-CN-
Pt(NH3)2}-{Cyt}]+ and over extended time periods, Cyt is cleaved from the PtII 
complex as well, nicely confirming the double prodrug concept (Scheme 20).  
 
Scheme 20: Drug release mechanism of prodrug B12 with a transplatin linker. 
 
 
Figure 7: ESI-MS spectra of product mix from reduction of 4 with Zn/NH4Cl: 
immediately after the reduction (left) and of the same mix after one day (right).
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III.2.5 In vitro cytotoxicity of B12 double prodrug 
Prodrugs or double prodrugs must not necessarily release their cargo before reaching 
their targets and therefore, the cytotoxicity of these compounds is a central concern. 
To assess if 4 was essentially non-toxic (no release of Cyt) or as toxic as the native 
drug, we investigated the in vitro cytotoxicity on the human chronic myelogenous 
leukemia cell line K562. For comparison, the double prodrug 4, pure Cyt and 
chemically reduced 4 were studied. The double prodrug 4 showed an IC50 in the 
nanomolar range (230 ± 62 nM) which is much lower than or comparable to the IC50 
for published B12-prodrugs; for instance, the cisplatin conjugate of B12 1 displayed an 
IC50 value of about 8 µM on a A2780 cell line126 and a cobalt bound colchicine 
derivative of B12 an LC50 value of about 40-300 nM on different cell lines.72 This IC50 
value mirrors the high cytotoxicity of Cyt (IC50 = 30 ± 5 nM), released from 4 via a 
slow, double cleavage process. Reduction of 4 with Zn/NH4Cl provided a convenient 
approach to examine cytotoxicity of the cleaved drug. Accordingly, the released 
complex [trans-Cyt-CN-Pt(NH3)2]+, being the active compound, exerted a similar 
cytotoxicity (IC50 = 30 ± 11 nM) as Cyt itself. In this approach, Cyt bound to PtII, 
represents a single prodrug. After cell uptake, Cyt is cleaved from PtII and exerts its 
cytotoxicity, comparable to pure Cyt. In the two-step release mechanism above, 4 is 
first taken up by the cell, the complex [trans-Cyt-CN-Pt(NH3)2]+ is enzymatically 
cleaved from B12 and then the Cyt is set free by substitution. The obtained 
approximately eight times lower IC50 value is reasonable, taking the different 
chemical and biological processes related to the double-prodrug approach into 
account. A similar trend was also observed for other B12 based single prodrugs.126 The 
IC50 of 4 reflects therefore a realistic effect of the double prodrug 4. 
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III.3 {Imaging agent}-{B12} conjugates 
III.3.1 Fluorescent B12 derivatives  
Fluorescence microscopy has high spatial resolution, which makes it a robust 
visualization technique for subcellular accumulation of compounds. With a 
millimetre-ranged resolution, -radioimaging is widely applied in in-vivo 
visualization.127 We initially aimed to produce a [99mTc]-analogue of 22 from the 
precursor 21. A complementary pair of radioactive and fluorescent B12 derivatives 
would allow direct correlation of in-vivo and subcellular in-vitro imaging.  
The fluorescence of 20 was based on the coordination of [bis(quinoline)] to 
[ReI(CO)3]+. This type of complexes was found to have long emission lifetime, good 
quantum yield, and large Stokes’ shift suiting for biological application.128 Doyle et. 
al reported the conjugation of such [Re-bis(quinoline)] fluorophore to B12 22.66 We, 
however, did not observe fluorescence of 22. The quenching effect of B12 on 20 was 
tested by adding equivalent amount of B12 to a solution of 50µM 20. The fluorescence 
of 20 was severely quenched (Figure 8). The fragile fluorescent property of 22 was 
confirmed later78 by Doyle et. al.. Therefore, 22 was not studied further. 
 
 
Figure 8: Quenching effect of B12 on 20. 
 
The formation of {B12}-{dansylimidazole} conjugate 7 was characterized by the 
fourteen aromatic signals on 1H-NMR (five signals from B12 and nine signals from 
Dansylimidazole) (Figure 9). Similarly, compound 9 has seven aromatic 1H-NMR 
signals (five from B12 and two from NBD-CO-Hz) (Appendices).   
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Figure 9: 1H-NMR spectrum of compound 7, {B12}-{dansylimidazole}with a 
transplatin linker 
 
Dansylimidazole129 and NBD-CO-Hz130 (Scheme 21) were not severely quenched by 
B12 (Figure 10). This is similar to the conjugation of Dansyl to B12 via [cis-Pt(NH3)2-
CN-imidazole]+ bridge.131 Dansyl fluorophore was previously conjugated to the Co-
center of Cbl via a propylamine linker (Scheme 8,b); however, fluorescence was 
completely quenched by Cbl.75 As fluorophore-corrin interaction was accounted for 
the quenching effect of Cbl, the retained fluorescence of 7 hinted that the linker [cis/ 
trans-Pt(NH3)2-CN-imidazole]+ oriented the dansyl fluorophore further away from the 
corrin ring compared to propylamine linker.  
 
Figure 10: Emission spectrum of 7 (left) and 9 (right) at a concentration of 50µM. 
Excitation wavelengths were 330nm and 483nm, correspondingly. 
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Compounds 7 and 9 were stable in water and light. The fluorophores were, however, 
cleaved off in the presence of HSA. 
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Scheme 21: Structures of B12 conjugates with fluorophores dansylimidazole (left) and 
NBD-CO-Hz (right) via the transplatin linker.
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III.3.2  [99mTc]-labeled-B12 prodrugs 
III.3.2.1 Synthesis of B12 prodrugs 
The tridentate [N,N,O] ligand 12 was chelated to [ReI(CO)3]+ to form 13 (Scheme 22) 
before coupling to B12. In this manner, competitive coordinations of [ß-CN-]-[ReI] and 
[N,N,O]- [PtII] were avoided.112 Both {ReI(CO)3}-{B12} conjugates, 16 and 28, posed 
ß-CN- as the only coordination site to PtII in the last step (Scheme 23). Conjugation of 
the tridentate ligand to {B12} resulted in additional four aromatic 1H-NMR signals for 
compounds 14-17 and 26-29 (Appendices). 
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Scheme 22: Reaction pathway to produce chelate ligand 12 and its Re-complex 13. 
  
[99mTc]-labeled-products are of low concentration as [99mTcO4]- is commercially 
available only at 10-8-10-7M.  As the coordination of [ß-CN-]-[PtII] requires mM-
concentration,79 the synthesis order to produce {99mTc}-{B12}-{cisplatin} conjugates, 
18 and 30, was different from their cold Re-analogues. The [N,N,O] tridentate ligand 
remained open during the formation coordinative [ß-CN-]-[PtII] bond. Only thereafter 
it was chelated with [99mTc(CO)3]+ (Scheme 23). The final, labeled products were 
characterized by comparing HPLC retention times with their cold Re-analogues, 17 
and 29. The ca. 5 minute-difference of elution time between the labeled products and 
their cold starting materials, 15 and 27, allowed convenient purification by HPLC 
(Figure 11). 
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Scheme 23: Reaction pathways for producing TC-binder 17 (above), non-binder 29  
(below) and their 99mTc-labeled analogues 18, 30. 
 
Figure 11: HPLC traces of radioactive 18, 30 with respect to the cold analogues 17, 
29 and the starting materials 15, 27.
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III.3.2.2 Affinity of B12 prodrugs to transcobalamin 
Crystal structure of holo-TC pointed out that the ribose 5’-OH did not involve in TC 
binding (Scheme 19).64 The ribose-derivative 17 indeed showed ΔTm similar to those 
of B12. This confirmed that it maintained interaction with all Cbl transport proteins. 
As Tc and Re share analogous properties owing to “lanthanide contraction”, a 
biological system does not distinguish 17 from 18. We, therefore, conclude that 18 
also holds affinities to HC, TC, and IF. 
In contrast, Scheme 19 showed H-bonds between the b-side of Cbl-OH2 and the C-
terminal β-domain of TC.64 This indicated that modification at the b-side is critical to 
Cbl-TC affinity. In a previous publication, binding to TC was deteriorated by a b-
side-derivative of B12.70 This increased the tumor-selectivity of the compound’s 
dissemination in mice. HC was appointed to mediate the tumor uptake. Following this 
strategy, compounds 29 and 30 were also derivatized at b-side to increase tumor-
selectivity. Indeed, ΔTm values of 29 with TC and IF indicated it was not bound to 
both proteins (Figure 12) as the two values were in the same range with those of Cbi 
(Figure 4). Based on the “lanthanide contraction”, we conclude that 30 also lost 
affinity to both TC and IF. 
 
 
Figure 12: Thermal shift of 17 and 29 to transport proteins. 
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III.3.2.3 Cell uptake of B12 prodrugs  
The importance of TC in mediating uptake of 18 and 30 was studied on leukemia 
K562 culture. The Cbl-and-folic-acid depleted medium was obtained commercially 
and FCS was treated with QUSO in order to exclude background TC/Cbl.83 
Internalization of TC-18 was up to 10-20 times higher than free 18 whilst the 
presence of TC did not affect significantly cellular import of 30 (Figure 13). As K562 
cells do not produce TC,132 the added TC accounted for the total TC in culture. The 
results confirmed that a Cbl with affinity to TC benefits from increased cellular 
import of TC-mediated-endocytosis.  
 
  
Figure 13: Relative uptake of 18 and 30 in the presence and absence of TC. 
 
ICPMS is a reliable technique for trace element analysis, especially metals. It is 
woven from the robust sample atomization of argon plasma and the sensitive 
detection of mass spectrometry. A nebulizer turns liquid sample into aerosol of fine 
droplets, which will be introduced into a spray chamber. This step excludes larger 
droplets and allows only small-sized droplets to enter the 6000oC plasma of the ICP 
torch. The high temperature dries the droplets out and atomizes the samples. The 
atoms subsequently lose an electron and single-charged ions are formed. The ions 
pass through an interface before reaching the vacuum of mass spectrometer. A 
quadrupole filters out neutrons and photons. Its voltage can be set to allow only ions 
with certain preset mass-to-charge ratio to hit the mass detector (Figure 14). 
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Figure 14: Sketch of an ICPMS instrument.133  
 
ICPMS can measure quantitative correlation of the transition metals (59Co, 195Pt, and 
187Re) in B12 derivatives, which revealed their intracellular distribution (Figure 15). In 
this experiment, the leukemia culture was treated with a high dose of Cbl (ca. 200µg) 
compared to a healthy person’s daily intake (4µg/day)45, 134 and the TC-deficiency 
treatment dose (ca. 0.5-2 mg/ week).135 The total uptake only accounted for less than 
0.1% of the administered dose (B12 derivatives and Cbl-OH2), which is low compared 
to 4% and 1% uptake for 50ug and 1-2mg dose in human.136 This is in agreement with 
the observation that the absorbed Cbl decreased with increasing dose.134, 136 80% of 
the administered dose remained in culture medium. The rest was probably membrane-
bound and thus lost in the washing steps. Except for B12, the absolute uptake was 
indeed high (ca. 30-40 pmol/mg protein) (Figure 15). It was ca. 5 times higher than an 
earlier report of Cbl content in liver (ca. 7 pmol/ mg protein). Liver was reported to 
store the highest Cbl amount in the body.134, 137 
Results and discussion 
  
41 
 
Figure 15: ICPMS uptake of platinated B12 prodrugs. Cisplatin, B12, and Cbl-OH2 
were used as control samples. 
 
Owing to different different cellular internalization pathways, the subcellular amounts 
of cisplatin are much higher than other platinated B12 prodrugs 1, 4, 17, and 29 
(Figure 15). In case cisplatin were cleaved from B12 structure before cellular 
internalization, the Pt-signals of 1, 17, and 29 would increase to the level of native 
cisplatin. However, the Pt-signals of these prodrugs remained rather similar to their 
Co-signals, which were close to the Co-signal of control Cbl-OH2. This confirmed 
that the B12 derivatives protected properly cisplatin. 
As apo-TC was not added in this assay, calf serum (10%) was the only source of TC 
in the culture. TC in calf serum can exist in both apo- and holo-forms. It was known 
that TC concentration in human serum is ca. 1nM, 10% of which is in the holo-
form.13 Though the exact quantity of apo-TC in culture was not determined, it was 
unlikely to be sufficient to transport the high-dose of administered Cbl (120 nmol). 
The background Cbl, which was found to be ca. 0.1 nmol, would certainly occupy 
available apo-TC, if any. Figure 15 showed an unexpected lower uptake of B12 
compared to that of the prodrugs. Even more surprisingly, it was also lower than 
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uptake of Cbl-OH2. As all administered Cbls, except for 29, bind well to TC, these 
findings confirmed that the observed internalization was not based on the regular TC-
mediated endocytosis.  
Cbl-OH2, similar to other platinated B12-prodrugs, is a charged molecule whilst B12 is 
a neutral compound. This indicated the existence of a charge-dependent uptake 
mechanism that neutral molecule like B12 was not included. Whether charged Cbl 
compounds were distinctly recognized by a Cbl-specific receptor or they actually 
passed ionic channels on cell membrane requires further study. Behavioral differences 
between charged and neutral B12 prodrugs were indeed previously observed.126 
Besides, uptake difference between B12 and Cbl-OH2 was earlier reported in human 
skin fibroblasts culture. In the presence of 10% serum, Cbl-OH2 was better 
internalized and retained than B12.138 The observation was, nevertheless, not 
rationalized.  
TC-independent uptake of Cbl was previously reported.139-142 HeLa cells internalized 
only 1-2% of free B12 with respect to holo-TC.139 This agreed with a later finding that 
free Cbl supported cell growth ca. 100 to 1000-fold less efficiently than holo-TC.83 
These data indicated the existence of an uptake mechanism which is less efficient than  
the commonly-known TC-dependent pathway.  However, the uptake of free-Cbl 
appeared to be dependent on the cell type. It was found to exceed 20% of holo-TC 
uptake in human skin fibroblasts.140 It was proposed that free-Cbl could be 
internalized by either a cell membrane receptor or a serum protein. Berliner proposed 
a free B12-specific receptor on the cell membrane (Scheme 24). Hitzig suggested an 
α2-globulin-like protein in serum. In the latter experiment, a surplus dose of free B12 
(3 mg or 2.2 µmol/week) sufficed to correct TC congenital deficiency.143 The 
appearance of an α2-globulin-like protein was detected. It was found to increase the 
B12 binding capacity. These findings, together with our suggestion of the charged-
dependent Cbl uptake reflected once again the complexity of Cbl dissemination. 
Many pathways were uncovered; however, the complete understanding was still not 
achieved. 
The different uptake patterns between 17 and 29 are puzzling. The [Re]-chelate was 
attached to the B12 structure through a carbamate bond in 17. Equivalent amounts of 
[59Co] and [187Re] in 17 indicated that the carbamate bond remained intact after cell 
internalization. [59Co]/[187Re] signals are lower than that of [195Pt] in 1, 4, and 17. It 
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was possibly because the coordination CN-Pt bond is not as stable as the carbamate 
bond. If [195Pt]-fraction fell off, it would be internalized via the more efficient 
cisplatin import pathway.  
The abnormal increase of [187Re] in 29, on the other hand, hinted that the amide bond 
was possibly hydrolyzed before cellular entrance. This implied the lower bond 
strength of amide relative to carbamate. On the other hand, there may be protein 
involvement in weakening the amide bond as it was located at a critical site for 
protein interaction (b-side) whilst the ribose side was known to not influence affinity 
of Cbl to proteins.  
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Scheme 24: Cellular uptake pathway for free B12, proposed by Berliner et al.140
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III.3.3  [57Co]-labeled B12 prodrug 
The [57Co] analogue of [{cis-Pt(NH3)2}-{B12}]+ conjugate 1 was previously 
prepared.144 However, significant activity loss to the reaction flask’s wall was 
observed. It affected further in-vitro assays on the compound. In this project, 33 was 
successfully synthesized in a straightforward procedure. The γ-counter reading 
indicated ca. 88% of the radioactivity was recovered. Identity of the purified product 
was confirmed by cross-comparison of HPLC retention time with that of 1 (Figure 
16). The product 33 has good stability. After four days (r.t., 0.9% NaCl), ca. 21% of 
33 was decomposed to [57Co]-B12. Though 18 behaved similarly to 1, 33 represented 
the closest structure similarity. It can serve as a good model to gain knowledge about 
behaviour of 1.  
 
Figure 16: HPLC traces of B12, 1 and 33 confirm successful coordination of [57Co]-
B12 to [cis-Pt(NH3)2Cl]+.
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IV Conclusions 
The primary aim of the project was to study the coordination of metallodrugs to 
vitamin B12 via the CN--bridge. In contrast with cisplatin, other metallodrugs did not 
form stable coordinative compounds with B12 owing to steric restriction of both B12 
and the drugs. Most metallodrugs were designed with spacious geometries to achieve 
specific interaction with biomolecules. Polyaryl or cyclic ligands were commonly 
found. This sumptuous asset of metallodrugs hindered formation of stable conjugates 
with B12. Sufficient stability was only achieved with most small molecules like cis- 
and transplatin. Besides, expansion of [M] out of the [PtII] border requires, in many 
cases, non-chromatographic purification. The availability of [M] and the convenience 
of separation techniques determine the success of this approach. 
Extra space between drugs and bulky B12 was achieved by extending the CN-bridge 
into the [trans-Pt(NH3)2-CN]+-bridge. This reduced the risk of structural restrictions 
in the conjugate. The double prodrug 4 is a good example of this strategy. It was 
stable at physiological condition. The delivery pathway of B12 was preserved. More 
importantly, 4 was cytotoxic owing to a two-step release of the native drug. In 
addition, fluorophores were conjugated to B12 via [trans-Pt(NH3)2-CN]+-bridge. 
Severe quenching effect of B12 was not observed.  
B12 derivatives were labeled with either [57Co] or [99mTc] as cellular distribution of 
these products can be measured. Derivatization was at both the corrin side chains and 
the back loop. The presence of TC enhanced uptake. This once more highlighted the 
importance of TC in studying biological behaviors of B12 derivatives. B12 prodrugs 
were, however, still internalized independent of TC. This uptake was measured by 
following signals of transition metals (59Co, 195Pt, and 187Re) in prodrug structures. 
This strategy allowed comparison between the prodrug and the native metallodrug. A 
lower uptake was observed for the prodrug, which was in agreement with lower 
cytotoxicity. Unexpectedly, this study showed that charged Cbls were preferably 
internalized into cells. This is noteworthy for future design of B12 biological 
conjugates. 
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In conclusion, drugs (organic and metallo-compounds) and fluorophores can be 
conveniently conjugated to B12 via the ß-CN- bridge, whether or not extended by a 
[trans-Pt(NH3)2]2+-link. Coordination at the ß-CN- was indicated by IR. Conjugation 
of aromatic drugs, fluorophores, or tridentate ligands resulted in the appearance of 
corresponding aromatic 1H-NMR signals in addition to the ones from B12. This is a 
reliable fingerprint to characterize such complex B12 derivatives. Inside the cells, the 
axial moieties are reductively released together with [trans-Pt(NH3)2-CN]+. The 
original drug or probe will subsequently be cleaved to exhibit their activities. Cellular 
internalization can be increased by bringing charges to structure of the conjugates. 
Biological behaviors of these conjugates can be measured by attaching a radioactive 
entity into their structures of by simply measuring the metal correlation.  
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V Outlook 
Whilst uptake of the B12 prodrugs was reported for K562 cancer cell line in this 
thesis, the measurement of these compounds in a control healthy cell line shall be 
included. This would allow comparison about the targeting efficiency of B12 prodrugs. 
The fact that B12 did not quench dansyl and NBD-CO-Hz introduced at the cis- and 
trans-[Pt(NH3)2-CN-imidazole]+-bridge deserves further investigation (Scheme 
25).131 It was previously reported that propylamine-bridge did not prevent dansyl 
from being quenched by B12. The question then lies on what made a key difference 
between the metal-complex and organic bridges: whether the geometry of Pt-
complexes or the addition of an imidazole played a more essential role in orienting 
the fluorophore away from the coring ring. In addition, the actual stability of such 
fluorescent B12 derivatives shall be assessed in complex with TC before cell 
visualization experiments. 
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Scheme 25: Structures of three different {B12}-{dansyl} conjugates via [cis-/ trans-
Pt(NH3)2-CN-imidazole]+ (7 and middle) and propylamine bridges (right).75, 131. 
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The drug loading capacity of B12 is generally considered to be a limiting factor for its 
use as a delivery agent. This problem can be overcome if the [CN-Pt]-bridge complex 
have aromatic N-heterocycle ligands instead of NH3. Such ligands can coordinate to 
additional cisplatin molecules. An example is [Pt(triazine)3-CN]2+-bridge, which can 
allow total coordination of six cisplatin molecules (Scheme 26). 
As transplatin allowed the coordination of other moieties into B12, it is interesting to 
know if it can allow the coordination of a second vitamin B12. The resulting sandwich 
dimer has a complex structure which may be interesting for catalysis purpose 
(Scheme 26).   
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Scheme 26:  Structures of a multi-cisplatin-B12 conjugate (left) and a sandwich dimer 
B12 (right).
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VII Experimental section 
VII.1 Materials and methods 
Chemicals were purchased from Sigma, Fluka, and Strem. HPLC analyses were 
performed using a Merck-Hitachi L-7000 system equipped with a diode-array UV/Vis 
spectrometer. The following HPLC columns were used: column 1, Macherey Nagel 
Nucleosil C18 (5 m, 100 Å, 250 mm x 3 mm); column 2, Agilent Zorbax GF-250 (4 
m, 250 mm x 9.4 mm); column 3, Macherey-Nagel Nucleodur C18 Gravity (5 m, 
250 mm x 3 mm). The following solvent systems were used: solvent system 1, 0.1% 
TFA (solvent A), MeOH (solvent B); solvent system 2, 130 mM NaCl, 20 mM 
Na2HPO4, pH 7 (solvent A); solvent system 3, 50 mM TEAP, pH 2.5 (solvent A), 
CAN (solvent B), solvent system 4, 0.1% TFA in 10% MeOH (solvent A), MeOH 
(solvent B). The following solvent gradients were used: gradient 1, 0-5 minutes: 75% 
A, 5-30 minutes: 0% A; gradient 2, 0-5 minutes: 50% A, 5-15 minutes: 40% A, 15-40 
minutes: 40% A; gradient 3, 0-20 minutes: 100% A; gradient 4, 0-3 minutes: 100% A, 
3-6 minutes: 75% A, 6-12 minutes: 66% A, 12-23 minutes: 0%A; gradient 5: 0-
5minutes: 100%A, 5-15 minutes:  0%A, 15-25 minutes: 0%A. Preparative HPLC 
purification was performed on a Varian Prostar system with two Prostar 215 pumps 
and a Prostar 320 UV/Vis detector, using Macherey Nagel Nucleosil C18 (7 m, 100 
Å, 250 mm x 40 mm) and at a flow rate of 35 ml/ minute. MeOH was removed from 
the product fractions under vacuum, the products were then liophilized. Product purity 
was analyzed by analytical HPLC, IR, and NMR. IR spectra were recorded by a Bio-
Rad FTS-45 spectrometer with samples in compressed KBr pills. NMR spectra were 
recorded by a Bruker DRX 500 MHz spectrometer. Chemical shifts were reported 
relative to residual solvent protons and carbons. The chemical shifts of 195Pt NMR 
spectra were relative to Na2PtCl6 in D2O. 
Lysis buffer was prepared from150 mM NaCl, 20mM HEPES buffer, 1 mM EDTA, 
0.5% Triton X-100 (Pharmacia Biotech AB), 1% protease inhibitor cocktail (freshly 
added), 1 mM NaVO3 (freshly added), NaCl/ KCl (30mM/ 120mM). 
All aqueous solutions for ICPMS measurement were prepared in purified water 
(>18.2MΩ) from Milli-Q deionization unit. Standards and samples were prepared in a 
mixture of HNO3 0.65% : HCl 1%.  
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VII.2 Synthesis 
b-carboxylic acid of vitamin B12 23,60 N-tert-butyloxycarbonyldiamines 10 (Scheme 
22),145 [NEt4]2[ReBr3(CO)3],146 and [99mTc(OH2)3(CO)3]+147 were prepared according 
to literature. Compounds [cis-Pt(NH3)2Cl{B12}][CF3CO2] 1 and [trans- Pt(NH3)2Cl-  
{B12}][CF3CO2] 2 were synthesized according to previous publications.79, 113 
 
[Ru(C6H6)(en){B12}][PF6]2 (3)  
25.3 mg [Ru(C6H6)(en)Cl][PF6]93 (60.24 mol) was mixed with 15.2 mg AgPF6 (60 
mol) in 2 ml H2O at 40oC overnight. The precipitate was filtered away and the 
yellow liquid was mixed with 47.9 mg B12 (35.3 mol). The reaction was left at 50oC 
for one day. The purple precipitate was washed with cold water and dried (28 mg, 
42%). 
1H NMR (500 MHz, D2O, 300K) : 0.48 (s, 3H, C20), 0.98 (m, 1H, C60), 1.12 (m, 
1H, C41), 1.29 (m, 6H, C46, Pr3), 1.46 (s, C47, 3H), 1.50 (s, C36, 3H), 1.51 (s, C54, 
3H), 1.85 (s, C25, 3H), 1.94 (m, 2H, C55, C60’), 2.1 (m, 7H, C41’, C42, C48, C30), 
2.24 (d, 1H, J=12.5Hz, C37), 2.30-2.31 (d, 6H, B10, B11), 2.48 (m, 4H, C26, C31), 
2.61-2.75 (m, 14H, C35, C53, C49, C55, Ruen(CH2)2), 2.83 (m, 2H, C18, C56), 2.99 
(m, 1H, Pr’1), 3.46 (m, 1H, C13), 3.56 (m, 1H, C8), 3.65 (m, 1H, Pr1), 3.79 (m, 1H, 
R’5), 4.08 (m, 1H, R4), 4.15 (d, 1H, J=10Hz, C19), 4.28 (m, 1H, C3), 4.32 (m, 2H, 
R2, Pr2), 5.71 (s, 6H, Ruar), 6.12 (s, 1H, C10), 6.38 (d, 1H, J=4.5Hz, R1), 6.47 (s, 
1H, B7), 7.03 (s, 1H, B2), 7.33 (s, 1H, B4). IR (KBr, cm-1): 2162 (CN). ESI-MS m/z: 
 797.3[M]2+.
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[trans-Pt(NH3)2(Cyt){B12}][CF3CO2]2 (4)  
To a solution of 25.4 mg (15.7 mol) 2 in 1.5 ml water, 15.4 mg (63.3 mol) Cyt was 
added. The mixture was stirred at 40oC for one day. Compound 4 was collected after 
purification with preparative HPLC, solvent system 1, and gradient 1 (11.1mg, 39%). 
1H NMR (500MHz, MeOD, 300K) : 0.39 (s, 3H, C20), 1.26-1.38 [m, 14H, C41 
(1H), C46 (3H), Pr3 (3H), C54 (3H), C36 (3H), C60 (1H)], 1.47 (s, 3H, C47), 1.76 (s, 
3H, C25), 1.80-2.15 [m, 9H, C55 (1H), C42 (1H), C60 (1H), C48 (2H), C41 (1H), 
C30 (1H), C42 (1H), C37 (1H)], 2.3 (m, 6H, B10&B11), 2.39-2.54 [m, 6H, C26 (2H), 
C55 (1H), C56 (1H), C31 (2H)], 2.59-2.63 (m, 6H, C35&C53), 2.70-3.03 [m, 6H, 
C49 (2H), C56 (1H), C37 (1H), C18 (1H), Pr1 (1H)], 3.66-4.27 [m, 14H, C13 (1H), 
C8 (1H), Pr1 (1H), R’5 (1H), R5 (1H), C19 (1H), R4 (1H), C3 (1H), Pr2 (1H), Cyt 
(5H)], 4.35 (m, 1H, R2), 4.71 (m, 1H, R3), 5.94(d, J=7.5, 1H, Cyt), 6.02 (s, 1H, C10), 
6.09 (d, J=4Hz, 1H, Cyt), 6.30 (d, J=3.5Hz, 1H, R1), 6.55 (s, 1H, B7), 7.09 (s, 1H, 
B2), 7.30 (s, 1H, B4), 7.95 (d, J=7.5Hz, 1H, Cyt). 195Pt NMR (107MHz, MeOD, 
20oC) : -2589. 31P NMR (200MHz, MeOD, 20oC) : 1.14. IR (KBr, cm-1): 2195 
(CN). ESI-MS m/z: 913.9 [M+1]2+, 1826.7 [M]+. 
 
[trans-Pt(NH3)2(Dac){B12}][CF3CO2]2 (5)  
To a solution of 56.8 mg (35 mol) 2 in 2 ml H2O, 24.3 mg (133 mol) Dac was 
added. The mixture was stirred at 38oC for one day. Compound 5 was collected after 
purification with preparative HPLC, solvent system 1, and gradient 1 (31 mg, 50%). 
1H NMR (500MHz, MeOD, 300K) : 0.38 (s, 3H, C20), 1.26-1.29 [m, 7H, C41 (1H), 
C46 (3H), Pr3 (3H)], 1.32-1.39 [m, 7H, C60 (1H), C54 & C36 (6H)], 1.47 (s, 3H, 
C47), 1.71 (m, 1H, C42), 1.79 (s, 3H, C25), 1.84-2.16 [m, 8H, C55 (1H), C48 (2H), 
C60 (1H), C41’ (1H), C30 (1H), C42’ (1H), C37 (1H)], 2.29 (m, 6H, B10 & B11), 
2.39-2.75 [m, 16H, C26 (2H), C56 (1H), C55’ (1H), C37’ (1H), C56’ (1H), C49 (2H), 
C31 (2H)], 2.82-2.86 [m, 2H, Pr1(1H), C18 (1H)], 3.40 (m, 1H, C13), 3.65-4.01 [m, 
10H, C8 (1H), Pr1 (1H), R’5 (1H), R5 (1H), Dac (6H)], 4.07-4.21 [m, 4H, R4 (1H), 
C19 (1H), C3(1H), R2 (1H)], 4.35 (m, 1H, Pr2), 4.71 (m, 1H, R3), 6.04 (s, 1H, C10), 
6.30 (d, J=3Hz, 1H, R1), 6.56 (s, 1H, B7), 7.08 (s, 1H, B2), 7.29 (s, 1H, B4), 7.96 (s, 
1H, Dac). 195Pt NMR (107MHz, MeOD): -2449. 31P NMR (200MHz, MeOD, 20oC) 
: 1.05. IR (KBr, cm-1): 2192 (CN). ESI-MS m/z: 1766.0 [M]+. 
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[trans-Pt(NH3)2(Ana){B12}][CF3CO2]2 (6) 
To a solution of 16 mg (9.9 mol) 2 in 1.2 ml water was added 10 mg (34 mol) Ana. 
The reaction was stirred at 40oC through one day. 6 was collected after purification 
with preparative HPLC, solvent system 1, gradient 1 (10.7 mg, 58%). 
1H NMR (500MHz, MeOD, 298K) : 0.41 (s, 3H, C20), 1.25-1.28 [m, 7H, C41 (1H), 
Pr3 (3H), C46 (3H)], 1.31-1.36 (m, 7H, C60 (1H), C54 (3H), C36 (3H)], 1.48 (s, 3H, 
C47), 1.71-1.80 [m, 20H, C55 (1H), C42 (1H), Ana (12H), C25 (3H), C60’ (1H), C48 
(2H)], 1.84-2.16 [m, 4H, C41’ (1H), C30 (1H), C42’ (1H), C37 (1H)], 2.29 [m, 6H, 
B10 (3H), B11 (3H)], 2.38-2.56 [m, 4H, C26 (2H), C56’ (1H), C55’ (1H)], 2.60 [m, 
6H, C55 (3H), C35 (3H)], 2.62-2.71 [m, 6H, C37’ (1H), C56 (1H), C49 (2H), C31 
(2H)], 2.81-2.85 [m, 2H, C18 (1H), Pr’1 (1H)], 3.61 (m, 1H, C8), 3.65 (m, 1H, Pr1), 
3.75 (m, 1H, R’5), 3.91 (m, 1H, R5), 4.08 (m, 1H, R4), 4.20 [m, 2H, C19 (1H), C3 
(1H)], 4.34 (m, 1H, R2), 4.39 (m, 1H, Pr2), 4.69 (m, 1H, R3), 5.58 (s, 2H, Ana), 6.04 
(s, 1H, C10), 6.29 (d, J=3Hz, 1H, R1), 6.55 (s, 1H, B7), 7.10 (s, 1H, B2), 7.30 (s, 1H, 
B4), 7.58 (d, J=2Hz, 2H, Ana), 7.65 (t, J=2Hz, 1H, Ana), 8.25 (s, 1H, Ana), 9.23 (s, 
1H, Ana). 195Pt NMR (107MHz, MeOD, 20oC): -2560. 31P NMR (200MHz, MeOD, 
20oC) : 1.15. IR (KBr, cm-1): 2239 (CN, Ana), 2193 (CN, B12). ESI-MS m/z: 938.9 
[M+H]2+, 1876.7 [M]+. 
 
[trans-Pt(NH3)2(dansylimidazole){B12}][CF3CO2]2 (7)  
21.2 mg (70.4 mol) dansylimidazole129 was added to a solution of 26 mg (16 mol) 
2 in H2O/ MeOH (3/2) (1.2 ml/ 0.8 ml). The reaction was stirred overnight at 45oC. 7 
was collected after purification with preparative HPLC, solvent system 1, gradient 1 
(3.5 mg, 12%). 
1H NMR (500MHz, D2O, 300K) : 0.46 (s, 3H, C20), 1.14 (m, 1H, C41), 1.28 (m, 
7H, Pr3, C46, C60), 1.42 (s, 6H, C54, C36), 1.49 (s, C47, 3H), 1.86 (s, 3H, C25), 2.29 
(d, 6H, B10, B11), 2.58 (s, 3H, C35), 2.61 (s, 3H, C55), 3.41 (m, 1H, Pr1), 3.45 (s, 
6H, N(CH3)2, dansyl), 3.49 (m, 1H, C18), 3.64 (m, 1H, R5), 3.78 (m, 1H, R’5), 3.93 
(m, 1H, B4), 4.08 (m, 1H, R4), 4.15 (m, 1H, C19), 4.21 (m, 1H, Pr2), 4.31 (m, 2H, 
C3, R3), 6.11 (s, 1H, C10), 6.38 (d, J= 3Hz, 1H, R1), 6.50 (s, 1H, B7), 7.05 (s, 1H, 
B2), 7.16 (m, 1H, imidazole), 7.32 (s, 1H, B4), 7.84 (m, 1H, imidazole), 7.96 (t, 
J=8.5Hz, 1H, dansyl), 8.05 (t, J=7.5Hz, 1H, dansyl), 8.08 (d, J=8Hz, 1H, dansyl), 8.70 
(d, J=8.5Hz, 1H, dansyl), 8.74 (d, J=8,5Hz, 1H, dansyl), 8.83 (d, J=7Hz, 1H, dansyl), 
9.00 (m, 1H, imidazole). ESI-MS m/z: 942.6 [M]2+.   
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[trans-Pt(NH3)2(imidazole){B12}][CF3CO2]2 (8) 
Only the byproduct 8 was formed when the reaction solvent mixture was 300 l H2O/ 
400l MeOH.  
1H NMR (500MHz, MeOD, 298K) : 0.42 (s, 3H, C20), 1.26 (d, J=6.5Hz, 3H, Pr3), 
1.30 (s, 3H, C46), 1.37 (m, 6H, C54, C36), 1.48 (s, 3H, C25), 2.30 (m, 6H, B10, 
B11), 2.61 (s, 6H, C55, C35), 3.42 (m, 1H, C18), 3.65 (m, 2H, Pr1, R5), 3.76 (m, 1H, 
R’5), 3.91 (m, 1H, C19), 4.09 (m, 1H, B4), 4.38 (m, 2H, R2, Pr2), 6.05 (s, 1H, C10), 
6.29 (d, J=3Hz, 1H, R1), 6.56 (s, 1H, B7), 7.07 (m, 1H, imidazole), 7.11 (s, 1H, B2), 
7.30 (m, 2H, B4, imidazole), 8.04 (s, 1H, imidazole). ESI-MS m/z: 826 [M]2+. 
 
[trans-Pt(NH3)2(NBD-CO-Hz){B12}][CF3CO2]2 (9)  
5.7 mg (21.4 mol) NBD-CO-Hz was added to a solution of 9.8 mg (6 mol) 2 in 1 
ml water. The reaction was stirred overnight at 40oC. 9 was collected after 
purification with preparative HPLC, solvent system 1, gradient 1 (3.7 mg, 33%). 
1H NMR (500MHz, MeOD, 300K) : 6.03 (s, 1H, C10), 6.28 (d, J=2.5Hz, 1H, R1), 
6.50 (d, J=12Hz, 1H, NBD-CO-Hz), 6.52 (s, 1H, B7), 7.09 (s, 1H, B2), 7.29 (s, 1H, 
B4), 8.59 (d, J=12.5Hz, 1H, NBD-CO-Hz). ESI-MS m/z: 925 [M]2+ 
 
[4-(pyridine-2-ylmethyl)amino]-buthylcarbamic acid tert-buthyl ester (11) and 
[4-(ethylacetate)-(pyridine-2-ylmethyl)amino]-buthylcarbamic acid tert-buthyl 
ester (12)  
11 and 12 were prepared as described in an earlier publication148 with following 
modifications. 
2 g 10145 (11 mmol) was dissolved in 100 ml MeOH. 1.3 g Pyridine-2-carbaldehyde 
(12 mmol) was added dropwise. The mixture was stirred at r.t. for 3h. The solvent 
was removed.  The imine product was dissolved in 50 ml EtOH. 1.5g NaBH4 was 
added in five portions during 2h. The solvent was removed. The residue was 
dissolved in diluted NaHCO3. The product was extracted with CH2Cl2. The organic 
phase was washed with water and dried with MgSO4. It was then filtered and the 
solvent was removed. The purification of 11 was performed on silicagel column 
(EtOAC, MeOH) (2.8 g, 91%).  
1H-NMR (200 MHz, MeOD, 300K): : 1.94-1.42 (m, 13H), 3.29 (m, 2H), 3.32 (m, 
2H), 4.37 (s, 2H), 7.41 (m, 1H), 7.49(m, 1H), 7.87(m, 1H), 8.63(m, 1H). Rf=0.28 
(NH4OH/ MeOH/ EtOAc, 1:10:89). ESI-MS: m/z=302.3 [M+H+Na]2+. 
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1.5 g 11 was mixed with 1ml TEA in 50 ml EtOH. The mixture was cooled to 0oC. 
600 l bromoacetic acid ethylesther was added dropwise within 5 minutes. After 
stirring at r.t. for 30 minutes at 0oC and 16h, the solvent was removed. The residue 
was dissolved in CH2Cl2. Extraction was performed with CH2Cl2/H2O. The organic 
phase was dried with MgSO4, filtered and the solvent was removed. The product 12 
(1.2 g, 60%) was collected as brownish oil.  
1H-NMR (200 MHz, MeOD, 300K): : 1.20-2.61 (m, 15H), 2.65 (t, J=6.6, 6.8 Hz, 
2H), 3.06 (d, J= 6 Hz, 2H), 3.36 (s, 2H), 3,89 (s, 2H), 4.13 (q, J= 7.2, 7, 7.2 Hz, 2H), 
4.73 (m, 1H), 7.13 (m, 1H), 7.47 (d, J=7.8 Hz, 1H), 7.63 (m, 1H), 8.51 (m, 1H). ESI-
MS: m/z=366.3 [M+H]+. 
 
4-{tricarbonylrhenium(I)-[(N,N,O)-(aceticacid)-(pyridin-2-ylmethyl)amino]}-
buthylcarbamic acid tert-buthyl ester (13)  
60mg (1.5mmol) NaOH in 1ml H2O was added to a solution of 176.2mg (0.48mmol) 
of 12 in 2.5ml MeOH. The reaction was stirred overnight. The pH was adjusted to 7 
with HCl 2M and saturated NaHCO3 was added to have a buffer medium. 374mg 
(0.48mmol) [NEt4]2[ReBr3(CO)3]146 in 7ml methanol was added. The mixture was 
refluxed at 60oC for 4 hours. The solvent was then removed. The product 13 was 
washed with H2O (235mg, 80%). 
1H-NMR (500 MHz, CD3CN, 300K): :1.4 (s, 13H), 1.48 (m, 2H), 1.81 (m, 2H), 3.08 
(m, 2H), 3.32 (d, J=17Hz, 1H), 3.56 (m, 2H), 3.70 (d, J=18Hz, 1H), 4.40 (d, 
J=15.5Hz, 1H), 4.57 (d, J=16Hz, 1H), 5.33 (s, 1H), 7.47 (t, J=6.5Hz, 1H), 7.59 (d, 
J=8Hz, 1H), 8.02 (t, J=8.5Hz, 1H), 8.77 (d, J=5.5Hz, 1H). IR (KBr, cm-1):2018, 1889,  
1872 (CO). ESI-MS: m/z=630.3 [M+Na]+.
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5’-{[4-(ethylacetate)-(pyridine-2-ylmethyl)]amino]-buthyl-carbamate}cyanocob- 
alamin (14) 
41mg 12 (112mol) was mixed with 1ml HCl 2M and 2ml H2O. The solution was 
stirred overnight to deprotect the Boc-group. The product was dried. 
100mg B12 (74mol) was dissolved in 2ml anhydrous DMSO. 25mg CDI (154mol) 
was added. The mixture was stirred at 60oC overnight. The above Boc-deprotected 
product was added together with 1ml TEA. The reaction was left for 2 hours until no 
further product was formed. The product 14 (27.5 mg, 22.5%) was separated by 
preparative HPLC, solvent system 1, gradient 1.  
1H-NMR (500 MHz, MeOD, 300K): : 8.72 (d, J=5Hz, 1H), 8.10 (t, J=8.5, 1H), 7.70 
(d, J=8Hz, 1H), 7.62 (t, J=7Hz, 1H), 7.25 (s, 1H, B7), 7.16 (s, 1H, B2), 6.6 (s, 1H, 
B4), 6.25 (d, J=3Hz, 1H, R1), 6.07 (s, 1H, C10), 4.62 (m, 1H, R3), 4.60 (s, 2H, CH2-
pyr of PAMA4), 4.55 (m, 1H, Pr2), 4.42 (m, 1H, R2), 4.29 (m, 2H, CH2O of 
PAMA4), 4.23 (m, 3H, C3, C19, R4), 4.20 (m, 1H, R5), 4.17 (m, 1H, R’5), 4.15 (s, 
2H, CH2CO of PAMA4), 3.66 (m, 2H, CH2N of PAMA4), 2.90 (m, 2H, CH2NH2 of 
PAMA4), 2.61 (m, 6H C53, C35), 2.41 (d, J=10Hz, 2H, C26), 2.32 (s, 3H, B10), 2.30 
(s, 3H, B11), 1.91 (s, 3H, C25), 1.78 (m, 4H, 2xCH2 of PAMA4)), 1,48 (s, 3H, C47), 
1.41 (s, 3H, C54), 1.39 (s, 3H, C36), 1.31 (t, J=4Hz, CH3 of PAMA4),  1.27 (d, 
J=6.5Hz, 3H, Pr3), 1,21 (s, 3H, C46), 0.49 (s, 3H, C20).IR (KBr, cm-1): 2137 (CN).  
ESI-MS: m/z= 824.3 [M+2H]2+, 1646.8 [M+H]+. 
 
5’-{[4-(ethylacetate)-(pyridine-2-ylmethyl)amino]-buthylcarbamate}{cisplatinum 
diammine-chloride-cyano}cobalamin (15)  
12mg (40mol) of cisplatin and 6.7mg (39mol) of AgNO3 was mixed together in 
1ml H2O in the absence of light. The reaction was stirred at 40oC for 4h. The mixture 
was filtered twice before 45mg (27mol) of 14 was added. The reaction was stirred at 
45oC for one day. Separation of 15 was performed on preparative HPLC, solvent 
system 1, gradient 1 (15mg, 29%). 
1H-NMR (500 MHz, MeOD, 300K): : 6.04 (s, 1H), 6.33 (d, J=5Hz, 1H), 6.47 (s, 
1H), 7.05 (s, 1H), 7.27 (s, 1H), 7.60 (m, 1H), 7.70 (d, J=10Hz, 1H), 8.10 (m, 1H), 
8.61 (m, 1H). 195Pt-NMR (107MHz, MeOD,  in ppm): =-2350.6. IR (KBr, cm-1): 
2200 (CN). ESI-MS: m/z=955.9 [M+2H]2+. 
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5’-{[4-tricarbonylrhenium(I)-[(N,N,O)-(aceticacid)-(pyridin-2-ylmethyl)amino]]-
buthyl carbamate}-cyanocobalamin (16)  
1ml TFA was added to 50mg (82.5mol) of (13) in 3ml CH2Cl2. After stirring for 1h 
at 0oC, the Boc group was fully deprotected from (13). The solvent was removed.  
To a solution of 150mg (0.11mmol) B12 in 3.5ml dry DMSO was added 24mg 
(0.15mmol) CDT. The mixture was stirred for 1 hour at 60oC. Then the above Boc-
deprotected product was added together with 4ml dry DMSO and 0.8ml TEA. The 
reaction was stirred overnight. DEE was added to precipitate the product mixture. 
Separation of 16 was performed on preparative HPLC, solvent system 1, gradient 1 
(31 mg, 14.5%) 
1H-NMR (500 MHz, MeOD, 300K): : 5.97 (s, 1H), 6.24 (s, 1H), 6.57 (s, 1H), 7.13 
(d, J=4Hz, 1H), 7.25 (s, 1H), 7.52 (m, 1H), 7.71 (t, J=6.5Hz, 1H), 8.07 (m, 1H), 8.81 
(d, J=5.5Hz, 1H). IR (KBr, cm-1): 2136 (CN); 2028, 1918, 1902 (CO). ESI-MS: m/z= 
1888 [M+H]+, 945 [M+2H]2+. 
 
{5’-[4-tricarbonylrhenium(I)-[(N,N,O)-(aceticacid)-(pyridin-2-ylmethyl)amino]]-
buthyl-carbamate}-{cisplatinumdiamminechloride cyano}cobalamin (17)  
12mg (40mol) of cisplatin and 6.7mg (39mol) of AgNO3 was mixed together in 
1ml H2O. The reaction was stirred in the absence of light at 40oC for 4h. The mixture 
was filtered twice. 1.9ml (19mol) of the filtrate was added to 22mg (11.6mol) of 
16. The reaction was stirred at 45oC for one day in the absence of light. The product 
was purified by preparative HPLC, solvent system 1, gradient 1 (20mg, 80%) 
1H-NMR (500 MHz, MeOD, 300K): : 5.99 (s, 1H), 6.26 (s, 1H), 6.58 (s, 1H), 7.14 
(s, 1H), 7.25 (s, 1H), 7.54 (m, 1H), 7.72 (m, 1H), 8.08 (d, J=6Hz, 1H), 8.80 (d, 
J=5Hz, 1H). 195Pt-NMR (107MHz, MeOD,  in ppm): =-2354. IR (KBr, cm-1): 2200 
(CN); 2026, 1916, 1904 (CO). ESI-MS: m/z= 1076.6 [M+2H]2+ 
 
{5’-[4-tricarbonyl-99mTc(I)-[(N,N,O)-(aceticacid)-(pyridin-2-ylmethyl)amino]]-
buthyl-carbamate}-{cisplatinumdiamminechloride cyano}cobalamin (18)  
Labeling of 15 with [99mTc(CO)3(OH2)3]+ resulted in the formation of 18. Reactions 
were performed following a previously published labeling procedure for vitamin B12 
derivatives.63 The authenticity of 18 was confirmed by comparing its HPLC retention 
time with that of 17. HPLC was perfomed on column 1, solvent system 3, and 
gradient 3 with a flow rate of 0.5 ml/ minute. 
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[4-(bis-quinolin-2-ylmethyl)-amino]-buthylcarbamic acid tert-buthyl ester (19), 
[4-tricarbonylrhenium(I)-[(N,N,N)-(bis-quinolin-2-ylmethyl)-amino]]-buthyl- 
carbamic acid tert-buthyl ester (20)  
Compound 19 and 20 were synthesized according to literature66 with some 
modifications. In details, 197 mg 10 (1 mmol) (97%) were mixed together with 345 
mg (2.1 mmol) of 2-quinolinecarboxaldehyde (97%) in 30 ml dichloroethane. The 
reaction was stirred under Ar. After 30 minutes, 667 mg (3 mmol) of sodium 
triacetoborohydride (97%) was added. The reaction continued overnight. The solvent 
was evaporated to collect 19 (250 mg, 53%). 
1H-NMR (500 MHz, MeOD, 300K): : 1.44 (s, 14H), 1.64 (m, 2H), 2.07 (m, 2H), 
2.66 (m, 2H), 3.07 (m, 2H), 4.05 (s, 4H), 4.75 (s, 1H), 7.54 (t, J=7Hz, 2H), 7.73 (m, 
4H), 7.81 (d, J=8Hz, 2H), 8.10 (d, J=8.5Hz, 2H), 8.16 (d, J=8.5Hz, 2H). ESI-MS: 
m/z=471.4 [M+H]+. 
158mg (335 mol) 19 was in 7 ml MeOH was mixed with 262 mg (340 mol) of 
[NEt4]2[ReBr3(CO)3]146 at 60oC for 4h. The solvent was evaporated. The product 20 
was washed with cold water (219mg, 88%). 
1H-NMR (500 MHz, MeOD, 300K): : 1.28 (m, 2H), 1.41 (m, 12H), 1.65 (m, 2H), 
2.03 (m, 2H), 3.16 (m, 2H), 3.88 (m, 2H), 5.05 (d, J=20Hz, 2H), 5.24 (d, J=20Hz, 1H) 
7.61 (m, 2H), 7.71 (m, 2H), 7.88 (m, J=8.5Hz, 2H), 8.03 (m, 2H), 8.55 (m, 4H). ESI-
MS: m/z=741.3 [M]+. 
 
5’-{[4-(bis-quinolin-2-ylmethyl)-amino]-buthyl-carbamate}- cyanocobalamin (21) 
and compound 5’-{[4-tricarbonylrhenium(I)-[(N,N,N)-(bis-quinolin-2-ylmethyl)-
amino]]-buthylcarbamate}-cyanocobalamin (22)  
To a solution of 95 mg (70 mol) B12 in 10 ml dry DMSO was added 17 mg (104 
mol) CDT. The mixture was stirred at 60oC for 30 minutes.  
35mg (74 mol) of (19) was dissolved in 1.5 ml CH2Cl2. 0.7ml TFA was added. The 
reaction was stirred at 0oC for one hour. The solvent was removed and 7 ml (49 mol 
B12) of the activated B12 above together with 1.3 ml TEA was added. The reaction was 
stirred overnight. The reaction mixture was precipitated with diethylether. Purification 
of the product 21 (12 mg, 14%) was performed on preparative HPLC, solvent system 
1, gradient 1.  
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1H-NMR (500 MHz, D2O, 300K): : 5.98 (s, 1H), 6.21 (s, 1H), 6.48 (s, 1H), 7.04 (s, 
1H), 7.13 (s, 1H), 7.40 (d, J=9Hz, 2H), 7.47 (t, J=7Hz, 2H), 7.68 (m, 4H), 7.85 (s, 
J=8.5Hz, 2H), 8.08 (d, J=8Hz, 2H). ESI-MS: m/z=1752.9 [M+H]+. 
36 mg (48 mol) 20 was dissolved in 1.5 ml CH2Cl2. 0.7 ml TFA was added. The 
raction was stirred at 0oC for one hour to remove the Boc-group. The solvent was 
subsequently removed. 3 ml (21 mol B12) of the activated B12 above was added. 
0.6ml TEA was added. The reaction continued overnight. The reaction mixture was 
precipitated with DEE. Purification of the product 22 (6mg, 14%) was performed on 
preparative HPLC, solvent system 1, gradient 2. 
1H-NMR (500 MHz, D2O, 300K): : 5.85 (s, 1H), 6.33 (m, 1H), 6.59 (s, 1H), 7.01 (s, 
1H), 7.31 (m, 2H), 7.41 (d, J=8.5Hz, 1H), 7.64 (m, 3H), 7.72 (m, 1H), 7.86 (d, 
J=8.5Hz, 1H), 7.96 (m, 2H), 8.11 (d, J=9Hz, 1H), 8.40 (d, J=8.5Hz, 1H), 8.52 (d, 
J=8Hz, 1H). ESI-MS: m/z=1011.9 [M+2H]2+, 2021.8 [M+H]+. 
 
Monocarboxylic acids b (23), d (24), and e (25) of vitamin B12 were synthesized  
according to a previous publication.60  
 
{b-[4-(ethylacetate)-(pyridine-2-ylmethyl)amino]-buthyl}- cyanocobalamin (26)  
To avoid the lactam formation, 94 mg 12 (258mol) was deprotected from the Boc-
group with 1 ml HCl 2M just before the coupling reaction. The product was 
liophilized and then it was mixed with 1ml TEA.  
50 mg (23) (37mol) and 83 mg TBTU (259mol) in a mixture of DMF/DMSO (5:1) 
were added. The reaction solution was stirred for ca. 2 hours to achieve full coupling. 
DEE was added to precipitate the product mixture. Separation of 26 was performed 
on preparative HPLC, solvent system 1, gradient 1 (23.4 mg, 39%).  
1H-NMR (500 MHz, MeOD, 300K): : 0.39 (s, 3H, C20), 1.14 (s, 3H, C46), 1.20 (m, 
3H, Pr3), 1.22 (m, 3H, CH3 of PAMA), 1.31 (m, 6H, C54, C36), 1.40 (s, C47, 3H), 
1.49 (m, 2H, C55, C42), 1.67 (m, 4H, 2 x CH2 of PAMA), 1.83 (s, 1H, C25), 2.21 (m, 
6H, B10, B11), 2.31 (d, J=8Hz, 2H, C26), 2.50 (s, 3H, C53), 2.53 (s, 3H, C35), 2.80 
(m, 2H, Pr’1, C8), 3.53 (m, 1H, C8), 3.63 (m, 1H, Pr1), 3.70 (m, 1H, R’5), 3.84 (m, 
1H, R5), 3.96 (s, 2H, CH2CO of PAMA), 4.03 (m, 1H, R4), 4.07 (m, 1H, C19), 4.13 
(m, 1H, C3), 4.19 (q, J=7Hz, 2H, CH2O of PAMA), 4.28 (m, 1H, R2), 4.42 (s, 2H, 
CH2-pyr of PAMA), 5.99 (s, 1H, C10), 6.22 (d, J=3Hz, 1H, R1), 6.51 (s, 1H, B4), 
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7.08 (s, 1H, B2), 7.20 (s, 1H, B7), 7.49 (m, 1H), 7.59 (d, J= 8Hz, 1H), 7.98 (t, J=8Hz, 
1H), 8.59 (d, J=5Hz, 1H). IR (KBr, cm-1): 2137. ESI-MS: m/z=802.6 [M+2H]2+. 
 
{b-[4-(ethylacetate)-(pyridine-2-ylmethyl)amino]-buthyl}-{cisplatinumdiammine-
chloride-cyano}cobalamin (27)  
4.8 mg cisplatin (16mol) was mixed with 2.7mg (16 mol) of AgNO3 in 1ml H2O. 
The reaction was stirred at 40oC for 4 hours in the absence of light. The solution was 
filtered twice before 15mg (9.4mol) of 26 was added. The reaction was stirred at 
45oC for one day. Separation of 27 was performed on preparative HPLC, solvent 
system 1, gradient 1 (12mg, 68%). 
1H-NMR (500 MHz, D2O, 300K): : 6.08 (s, 1H), 6.38 (d, 3Hz, 1H), 6.51 (s, 1H), 
7.09 (s, 1H), 7.31 (s, 1H), 7.64 (m, 1H), 7.74 (d, J=8Hz, 1H), 8.14 (m, 1H), 8.65 (d, 
J=5Hz, 1H). 195Pt-NMR (107MHz, MeOD,  in ppm): =-2360. IR (KBr, cm-1): 2197. 
ESI-MS: m/z=934.4 [M+2H]2+. 
 
{b-[4-tricarbonylrhenium(I)-[(N,N,O)-(ethylacetate)-(pyridine-2-ylmethyl)amino 
]]-buthyl}-cyanocobalamin (28)  
55mg (40mol) 23 in 8ml DMF was mixed with 119 mol Boc-deprotected 13. 2ml 
TEA was added. 62mg (193mol) TBTU in 5ml DMF was added. The reaction 
mixture was stirred at r.t. for 1h. The product mixture was precipitated upon the 
addition of DEE. Preparative HPLC with solvent system 1, gradient 1 were employed 
to purify 28 (32mg, 43%). 
1H-NMR (500 MHz, MeOD, 300K): : 6.07 (s, 1H), 6.28 (d, J=2.5Hz, 1H), 6.59 (s, 
1H), 7.14 (s, 1H), 7.25 (s, 1H), 7.55 (t, J=6.5Hz, 1H), 7.71 (d, J=5Hz, 1H), 8.08 (t, 
J=8Hz, 1H), 8.82 (d, J=5Hz, 1H),. IR (KBr, cm-1): 1893, 1912, 2024 (CO); 2137 
(CN). ESI-MS: m/z= 923.4 [M+2H] 2+, 1845.7 [M+H] +  
 
{b-[4-tricarbonylrhenium(I)-[(N,N,O)-(ethylacetate)-(pyridine-2-ylmethyl)amino 
]] -buthyl}-{cisplatinum-diammine-chloride-cyano}cobalamin (29)  
7 mg (23 mol) cisplatin was added to a solution of 3.9 mg (23 mol) AgNO3 in 1ml 
water. The mixture was stirred at 0oC for 4h in the absence of light. It was 
subsequently filtered twice. 25mg (13.6mol) of 28 was added to the filtrate. The 
reaction was stirred for one day at 45oC. Purification of 29 was performed on 
preparative HPLC, solvent system 1, gradient 1 (20mg, 69%). 
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1H-NMR (500 MHz, MeOD, 300K): : 5.99 (s, 1H), 6.28 (d, J=3Hz, 1H), 6.58 (s, 
1H), 7.14 (s, 1H), 7.28 (s, 1H), 7.55 (t, J=6.5Hz, 1H), 7.72 (d, J=7.5Hz, 1H), 8.11 (m, 
1H), 8.83 (d, J= 5Hz, 1H). 195Pt-NMR (107MHz, MeOD,  in ppm): =-2352. IR 
(KBr, cm-1): 1897, 1911, 2025 (CO), 2196 (CN). ESI-MS: m/z=1055.4 [M+2H]2+. 
 
{b-[4-tricarbonyl-99mTc(I)-[(N,N,O)-(ethylacetate)-(pyridine-2-ylmethyl)amino]]-
buthyl}-{cisplatinum-diammine-chloride-cyano}cobalamin (30)  
Compound 30 was labelled as described above for 18. 
 
{d-[4-(ethylacetate)-(pyridine-2-ylmethyl)amino]-buthyl}- cyanocobalamin (31)  
When 24 was used instead of 23, the respective product was 31.  
1H-NMR (500 MHz, MeOD, 300K): : 6.01 (s, 1H, C10), 6.28 (d, J=3Hz, 1H, R1), 
6.58 (s, 1H, B7), 7.11 (s, 1H, B2), 7.23 (s, 1H, B4), 7.3 (m, 1H), 7.56 (m, 1H), 7.8 (m, 
1H), 8.45 (m, 1H). ESI-MS: m/z= 1604.5 [M+H]+, 802.7 [M+2H]2+. 
 
{e-[4-(ethylacetate)-(pyridine-2-ylmethyl)amino]-buthyl}- cyanocobalamin (32)  
When 25 was used instead of 23, the respective product was 32. 
1H-NMR (500 MHz, D2O, 300K): : 6.05 (s, 1H, C10), 6.30 (d, J=3Hz, 1H, R1), 6.60 
(s, 1H, B7), 7.35 (s, 1H, B2), 7.26 (s, 1H, B4), 7.30 (m, 1H), 7.62 (m, 1H), 7.83 (m, 
1H), 8.50 (m, 1H). ESI-MS: m/z=802.6 [M+2H]2+. 
 
 [{cis-Pt(NH3)2-Cl}-{B12}][CF3CO2] (33)  
480 l [57Co]-B12 (1,75Ci/ml in sodium borate buffer pH 9.6 was adjusted to pH 5-6 
with TFA 5%. To this solution was added 212 l of freshly prepared mono-
aquocisplatin 100mM. The mixture was stirred for 9.5h at 50oC. Then it was loaded 
on C18-ec-sepak column. The Pt-residue was washed away with water. The product 
was eluted with MeOH. Eluted fractions of highest -radioactivity were pooled 
together.1ml of saline 0.9% was added. MeOH was then dried under N2. Comparing 
HPLC retention time of the product with the cold analogue 1 confirms the identity  
of 33.  
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VII.3 Reductive release of drug from double prodrug 
The reduction of 4 (100 M) was monitored at -700mV in 
tris(hydroxymethyl)aminomethane buffer (0.2 M, pH 8, 37oC). Pt net and Pt wires 
were working and counter electrodes. Reference electrode was Ag/AgCl. UV-Vis 
spectra were recorded every thirty minutes. 
In addition, 4 (8 mM) was also reduced by Zn pellets (1 g) in NH4Cl (1%) at r.t. The 
final product mixture was identified by ESI-MS and HPLC. Zn was filtered. The 
filtrate was diluted substantially into a range of concentration (10 nM-100 M) for 
cell viability assay.
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VII.4 Biological study 
VII.4.1 Binding of double prodrug 4 to human serum albumin  
A mixture of 200 M B12-derivatives and HSA in phosphate buffer (0.1 M, pH 7.4), 
0.9% NaCl was stirred at r.t. for three days. The binding process was followed by size 
exclusion HPLC (column 2, solvent system 2, and gradient 3). Decomposition of 4 
was followed by RP-HPLC column 1, solvent system 1, and gradient 1.  
VII.4.2 Affinity of double prodrug 4 to Cbl transport proteins  
DSF was applied to measure the affinity of B12-derivatives to transport proteins. DSF 
is a fluorescence-based method to measure protein stability and ligand-induced 
changes in protein stability.149 Transport proteins were incubated both alone and with 
different ligands. B12 was used as a non-selective binder and Cbi as a selective binder. 
Cbi binds only to HC. 
Preparation of recombinant Cbl transport proteins. Recombinant human (rh) HC 
(rhHC) and rhIF were expressed and purified as described elsewhere.150, 151 rhTC was 
expressed according to rhHC.151 In brief, the cDNA for human TC (pCMV6-TC 
RC200682), OriGene, Myc-DDK-tagged ORF clone of Homo sapiens TC, NCBI 
Reference Sequence: NM_000355.2, transcript variant 1 as transfection-ready DNA 
purchased by Origene (Lab Force, Nunningen, Switzerland) was cloned into the 
EcoRII/XhoI site of pcDNA4/myc-His A vector (Invitrogen AG, Basel) by standard 
molecular biology techniques. The primers (Microsynth AG, Switzerland) were 5’-
TAATACGACTCACTATAGGG-3’and5’CCGCTCGAGAGATCCACGCGGAACC 
AGCCAGCTAACCAGCCTCAGCTC-3’. All selected clones were verified by DNA 
sequencing (Microsynth AG, Balgach, Switzerland). HEK293 cells were transfected 
using Lipofectamine 2000 (Invitrogen AG, Switzerland) following the manufacturer’s 
instructions. Stable transfected cells were isolated and grown as described 
elsewhere.152 rhTC was purified using a Ni2+ affinity column. Absorption was carried 
out at r.t. with gravity flow. The resin was washed with 6 volumes of PBS, 6 volumes 
of PBS and 1M NaCl, and 6 volumes of PBS and 0.5M NaCl, 20mM imidazole. 
Elution was carried out with PBS, 300mM imidazole. The peak fractions were 
polished using a SuperdexTM 75 10/300 gel filtration column and ÄktaTM prime 
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system (Amersham Biosciences). Gel filtration was conducted at r.t. with a flow rate 
of 24 ml/h using PBS. The fractions with rhTC were then pooled and frozen at -20°C. 
A Rotor-Gene cycler (Rotor-Gene 5plex HRM, QIAGEN) was chosen for protein 
stability measurement by DSF. Stability measurements were performed in PBS. 
SYPRO® Orange (Invitrogen, cat. no. S6651) was used at 50x concentration. Protein 
concentrations were between 300-450 nM. Ligand concentrations were about 20 M. 
Excessive ligand was chosen to assure that total protein was ligand-bound. Thirty-six 
100 l samples were processed in 0.5 ml PCR tubes in the 36-Well Rotor of the 
Rotor-Gene cycler. HRM was programmed to ramp the temperature from 25°C to 
95°C. Data were collected every 0.5°C, with an equilibration time of two seconds. 
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VII.4.3 Cell viability assay  
The human chronic myelogenous leukemia (CML) K562 cell line was seeded in 96-
well plates (100l/well, 500 cells/well) and incubated (37°C, 95% air / 5% CO2) one 
day before treatment. Cells were maintained in RPMI 1640-medium (PAA) 
supplemented with 10% fetal bovine serum (PAA), penicillin (100 U/mL), and 
streptomycin (100U/mL) (Gibco). 100 l of drugs at different concentrations (10nM-
100M) were added to cells the next day. Cells were incubated for four days. 20l 
0.86mM resazurin was then added to each well. Incubation was continued for four 
hours. Fluorescence was measured at 590 nm emission (with an excitation wavelength 
of 540 nm) in the SpectraMax M5 microplate reader. Cells were treated with Cyt, 4, 
reduced mixture of 4. Vitamin B12, 2, and NH4Cl were also given to cells as control. 
Three experiments were performed on separate cell batches during three months.
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VII.4.4 Uptake measurement with [99mTc]-radiolabeling  
K562 cells were grown in complete media (RPMI-1640, 10% FCS). Before the assay, 
cells were transferred into RPMI-1640 medium depleted from B12 and folic acid (Cell 
Culture Technologies). The medium was supplemented with 1µM Homocysteine and 
1µM 5-methyltetrahydrofolic acid whereas serum was not added. Two 6-well plates 
were required. Each well contained 4x105 cells. In one plate, 3 wells were treated with 
(18) and the rest with (30). In the other plate, 3 wells were treated with TC-(18) and 
the rest with TC-(30) (2 equivalents of TC). Each well contained an amount of ca. 0.8 
ng B12 derivative. Subsequently, two plates were incubated for one day. Cell pellets 
were isolated by centrifugation (450xg, 4oC, 5 minutes). They were washed (x3) with 
PBS prior to measurement with a -counter. 
VII.4.5 Uptake measurement with ICPMS 
K562 cells were seeded in seven T-75 flasks. The seeding density was 3x106 cells/ 
flask. The culture medium was 12 ml RPMI-1640 with 10% FCS and penicillin-
streptomycyn (100U/ml). After 1 day of incubation, each flask was treated with 10µM 
of a compound. These included cisplatin, B12, Cbl-OH2, 1, 4, and 17. The remaining 
flask was not treated with any compound and served as the control sample. Cells were 
further maintained in culture for two days. Nucleic and cytosolic fractions were 
separated according to a previously published procedure with certain modifications.153 
In details, cells were centrifuged for 1 minute at 700xg and r.t.. The supernatant was 
discarded. Pellets were washed (x3) with 5ml PBS. Lysis was performed in 1 ml 
freshly- prepared ice-cold buffer of 150mM NaCl, 20mM HEPES buffer, 1mM 
EDTA, 0.5% Triton X-100, 1% protease inhibitor cocktail, 1 mM NaVO3, NaCl/ KCl 
(30mM/ 120mM). 20µl of the lysate was spared for protein determination (DC 
Protein Assay, Bio-Rad). The rest was centrifuged at 600xg, 4oC for 5 minutes. The 
pellet was washed (x3) with 1ml NaCl/ KCl (30mM/ 120mM) to isolate nuclei 
fraction. The supernatant was centrifuged at 5500xg, 4oC for 15 minutes. Cytosolic 
fraction was the supernatant part. The nuclei fractions were digested with 100µl 
concentrated HNO3. Both nucleic and cytosolic fractions were diluted 50 times for  
ICPMS measurement. 
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VIII Appendices  
 
 
1H NMR from ß-conjugate of B12 and dacarbazine 5. 
 
1H NMR from ß-conjugate of B12 and anastrazole 6. 
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1H NMR from ß-conjugate of B12 and imidazole 8. 
 
1H NMR from ß-conjugate of B12 and NBDCOHz 9. 
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1H NMR from ribose-conjugate of B12 and tridentate ligand 14. 
1H NMR from ribose,ß-conjugate of B12, tridentate ligand, and cisplatin 15. 
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1H NMR from ribose-conjugate of B12 and Re-chelate 16. 
 
1H NMR from ribose,ß-conjugate of B12, Re-chelate, and cisplatin 17. 
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1H NMR from b-conjugate of B12 and tridentate ligand 26. 
 
 1H NMR from b,ß-conjugate of B12, tridentate ligand, and cisplatin 27. 
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1H NMR from b-conjugate of B12 and Re-chelate 28. 
 
1H NMR from b,ß-conjugate of B12, Re-chelate, and cisplatin 29. 
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1H NMR from d-conjugate of B12 and tridentate ligand 31. 
 
1H NMR from e-conjugate of B12 and tridentate ligand 32. 
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